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(57)	 ABSTRACT
The present invention relates to a biologically active func-
tionalized electrospun matrix to permit immobilization and
long-term delivery of biologically active agents. In particular
the invention relates to a functionalized polymer matrix com-
prising a matrix polymer, a compatibilizing polymer and a
biomolecule or other small functioning molecule. In certain
aspects the electrospun polymer fibers comprise at least one
biologically active molecule functionalized with low molecu-
lar weight heparin. Examples of active molecules that may be
used with the multicomponent polymer of the invention
include, for example, a drug, a biopolymer, for example a
growth factor, a protein, a peptide, a nucleotide, a polysac-
charide, a biological macromolecule or the like. The inven-
tion is further directed to the formation of functionalized
crosslinked matrices, such as hydrogels, that include at least
one functionalized compatibilizing polymer capable of
assembly.
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CROSS REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of U.S. Provisional
Application No. 60/666,787, filed Mar. 31, 2005, the contents 10
of which are incorporated herein by reference.
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The work described in this application was sponsored by
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Number DMR-0210223, NASA under Contract Number
NAGS-01923 and NIH, Nanoscale Engineering, under Con-
tract Number I ROI EB003172-01. 	 20
FIELD OF THE INVENTION
The present invention relates generally to a composition
and method for the formation of functionalized polymer
matrices comprising a matrix polymer, a compatibilizing 25
polymer and a biomolecule or other small functioning mol-
ecule. In a more specific embodiment, the invention includes
heparin-containing electrospun polymeric fibers useful in
biological applications, for example, implantable systems for
drug delivery, tissue engineering or wound repair. In other 30
aspects the present invention relates to multicomponent poly-
mer matrices that display biologically beneficial properties,
for example, by also comprising therapeutic molecules
therein. In another important aspect the invention relates to a
polymer matrix, useful for the controlled release of a biologi- 35
cally active agent, such as for example, a drug, a biopolymer,
a biological macromolecule, and the like. The invention is
further directed to the formation of functionalized
crosslinked matrices, such as hydrogels, that include at least
one functionalized compatibilizing polymer capable of 40
assembly.
BACKGROUND OF THE INVENTION
Over the past two decades the development of novel drug 45
delivery systems has had a tremendous impact on medicine,
allowing for the improvement of many existing therapeutics
as well as enabling the use of entirely new therapies. Along
with these improvements there has been a move to miniatur-
ize drug delivery devices from the macroscale (>I mm) to the 50
macroscale (100-0.01 µm) or nanoscale (100-1 mu). One goal
of developing these devices is to provide for the in situ deliv-
ery of therapeutic compounds. Therefore, a main area of
investigation concerns the development of integrated systems
that combine the nanotechnology with therapeutic molecules, 55
for example, drugs, or biopolymers.
However, these new technologies must overcome several
crucial and significant obstacles. For example, new
approaches are required that allow for the delivery of
insoluble, or unstable compounds. In addition, these 60
approaches must address situations in which the therapeutic
molecule is rare, or difficult to purify. Furthermore, these
approaches must allow for localized delivery of potent com-
pounds, and provide for improved compliance by reducing
the chances of missing or erring in a dose. Lastly, these 65
devices cannot be so small that they are unable to deliver an
adequate dose.
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In addition, to date a number of peptides and proteins have
been explored for pharmaceutical applications by virtue of
their high biological activity and specificity. Despite potential
advantages offered by these drugs, their application may suf-
fer because of the high molecular weight, hydrophilicity and
low stability, which are reflected in poor biopharmaceutical
properties. In particular, peptides and proteins undergo rapid
clearance from the body, which takes place by a combination
of events including proteolysis, renal ultrafiltration, and liver
clearance.
The development of functionalized polymers that can elicit
specific biological responses, as well as the development of
methods to fabricate these biologically functionalized poly-
mers, is a viable approach for such therapeutic applications,
in which delivery of molecules such as those above is desir-
able. For example, the generation of fibrous matrices with
biological properties and fiber diameters commensurate with
those of the natural extracellular matrix (ECM) may permit
the development of novel materials for use not only in drug
delivery, but also in wound healing or tissue engineering.
Synthetic polymers, which can be designed to mimic some
functions of biopolymers, have been actively developed as
drug delivery matrices due to their industrial and scientific
value. They represent a primary polymeric vehicle for the
delivery of drugs and biomolecules, owing to their simple
synthesis, ease of processing, and range of physical proper-
ties. Polymers such as proteins, polysaccharides, and nucleic
acids, which are present as basic components in living organic
systems, have also found some use in drug delivery and bio-
materials applications, particularly for biopolymers such as
collagen and alginate, which have desired mechanical and
biological properties. There remains a significant need, how-
ever, for the facile production of polymeric materials in which
mechanical and biological properties can be easily modified
in a modular fashion, without relying solely on the naturally
occurring mechanical properties of the biological polymers
or the lack of biological activity of synthetic polymers.
One approach to the use of polymers in drug delivery
applications involves the response of a polymer system to
certain stimuli, which is a common process for biopolymers
in living organisms. Stimuli responsive polymers can provide
a variety of applications for the biomedical fields. The interest
in these polymers has increased dramatically due to their
promising potential. Among others, temperature and pH
responsive mechanisms have been investigated as they are
relatively convenient and effective stimuli in a variety of
applications. Such stimuli-responsive polymers have been
utilized in various forms, including cross-linked (penna-
nently) hydrogels, reversible hydrogels, micelles, modified
interfaces, and conjugated solutions, among others.
There has also been developing interest by the scientific
community in applying methods from engineering and the
life sciences to create artificial constructs directed to tissue
regeneration, and thus, providing a minimally invasive and
less painful way to treat patients. The basic protocol for the
tissue engineering approach includes isolating specific cells
by obtaining them through a biopsy from a patient, growing
them on a three-dimensional scaffold under controlled cul-
ture conditions, delivering the construct to the desired loca-
tion in the patient's body and directing new tissue formation
into the scaffold that will be degraded over time. Successful
regeneration of damaged organs or tissues based on tissue
engineering requires several critical elements, not the least of
which includes biomaterial scaffolds that serve as a mechani-
cal support for cell growth.
Materials are important in most tissue engineering strate-
gies as they can serve as a substrate on which cell populations
US 7,737,131 B2
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can attach and migrate, be implanted with a combination of
specific cell types as a cell delivery vehicle, and be utilized as
a drug carrier to activate specific cellular function in the
localized region.
The modification of biomaterials with bioactive molecules
has been found useful in designing biomimetic scaffolds that
can provide biological cues to elicit specific cellular
responses and direct new tissue formation. The surface and
bulk modification of materials withpeptide sequences or with
bioactive proteins or other biomolecules, for example, can
allow for the modulation of cellular functions such as adhe-
sion, proliferation and migration through alterations of pep-
tide concentration or its spatial distribution. A variety of cell
binding peptides have been introduced into three dimensional
networks through physical, chemical, photochemical, and
ionic crosslinking. The molecules have been attached to a
variety of polymeric substrates for varying applications, but a
need still remains for methods for simple modification of
materials with multiple bioactive molecules in a manner that
can control their release.
Electrospinning is an attractive approach to polymer pro-
cessing. The control of fiber diameter, porosity, and fiber
surface morphology makes electrospun fibers useful in a
range of applications including filtration, electronic, and bio-
medical applications. Electrospun fibers are ideal for use in
biomedical applications such as tissue engineering and drug
delivery due to the three-dimensional nanometer scale matrix
that can be quickly produced using small quantities of starting
material (<50 mg) on the laboratory scale. Larger matrices
can also easily be made via the scaling up of materials that
prove to have useful materials and biological properties on the
laboratory scale. Collagen, fibrinogen, chitosan, poly(lactic
acid), poly(L-lactide-co-p-caprolactone), and poly(D,L-lac-
tide-co-glycolide) are just a few of the polymers being inves-
tigated for use in electrospun drug delivery and tissue engi-
neering constructs due to their biocompatibility. Electrospun
fibers mimic the size scale of fibrous proteins found in the
extracellular matrix (50-150 mu) and the three-dimensional
nature of the matrix allows for cells to infiltrate the matrix and
proliferate. A variety of additional polymers can also be elec-
trospun into matrices for drug delivery, tissue engineering,
and other applications. For example, see Z. M. Huang, Y. Z.
Zhang, M. K. Kotaki and S. Ramakrishna, Composites Sci.
and Tech. 2003, 63, 2223-2253, (US Patent publication No.
US20030137069).
Although there have been reports of the use of electrospun
fibers as scaffolds for select drug delivery and biomaterials
applications, the incorporation of bioactive molecules has not
been widely exploited. In one example, tetracycline was
included in a solution of poly(lactic acid) (PLLA) and poly
(ethylene-co-vinyl acetate) and electrospun in a fiber mem-
brane to study the release profile of the fiber-encapsulated
drug. PLLA has also been studied as a matrix to incorporate
the drugs rifampin (to treat tuberculosis) and paclitaxel (anti-
cancer drug). Polymers loaded with both of these therapeutic
molecules could be fabricated into nanometer to micron
diameter electrospun PLLA fibers and used for delivery of the
drug.
While the development of functionalized polymers that can
elicit specific biological responses is of great interest in the
biomedical community, as well as the development of meth-
ods to fabricate these biologically functionalized polymers,
there is still a need for more facile methods to create biologi-
cally active functionalized matrices that permit immobiliza-
tion and long-term delivery of biomolecules and other small
functioning molecules, moieties, and/or particles.
For example, although there have been studies demonstrat-
ing the utility of functionalizing electrospun fibers, the func-
tionalization of electrospun fibers to confer specific biologi-
cal activity would be particularly advantageous for many
5 biomaterial applications, as such modification would permit
the fabrication of biomaterials that are structurally relevant
and that possess properties designed to treat or address spe-
cific problems. In addition, such incorporation could serve to
protect bioactive molecules, release them in relevant time-
io frame, and incorporate multiple such molecules. In particular,
the development of simple methods to produce multifunc-
tional electrospun fibers would advance the development of
electrospun fibers for biomedical applications.
Of such bioactive molecules, glycosaminoglycans have
15 been demonstrated to mediate a wide range of biological
activities such as cell adhesion, cell mobility, cell prolifera-
tion and tissue morphogenesis via binding to various cell
regulatory proteins such as the chemokines, growth factors,
enzymes, enzyme inhibitors, and extracellular matrix pro-
20 teins. The well studied glycosaminoglycan, heparin, is a lin-
ear, unbranched, highly sulfated polysaccharide chain, and it
is well accepted that the electrostatic interactions between the
sulfates of the glycosaminoglycan and basic residues of a
protein play an important role in binding. In particular, the
25 spatial orientation of the basic residues is a major determinant
of heparin-binding ability, and variations in the pattern of the
sulfation of the heterogeneous heparin therefore permit bind-
ing between heparin and a wide range of binding partners.
Accordingly, heparin has been incorporated into covalent
3o hydrogel delivery systems because of this ability to bind a
diverse set of proteins. In addition, we and others have dem-
onstrated that the interactions between heparin and specific
HBPs can also mediate the assembly of noncovalently asso-
ciated hydrogel networks (see, for example, N. Yamaguchi,
35 K. L. Kiick, Polysaccharide poly (ethylene glycol) star
copolymers as scalblds for the production of bioactive hydro-
gels, Biomacromolecules 6 (4) (2005) 1921-1930; N.
Yamaguchi et al., Rheological characterization of polysac-
charidepoly(ethylene glycol) star copolymer hydrogels,
4o Biomacromolecules 6 (4) (2005) 1931-1940; B. L. Seal, A.
Panitch, Physical polymer matrices based on affinity interac-
tions between peptides and polysaccharides, Biomacromol-
ecules 4 (6) (2003) 1572-1582).
Because hydrogels can mimic the high water content and
45 mechanical properties of natural tissues, they are prime can-
didates as carriers of bioactive agents, in bioadhesive sys-
tems, or as biorecognizable materials. Given that poly (eth-
ylene glycol), or PEG, is highly hydrophilic and generally
nonadhesive to proteins or cells, it has found widespread use
5o as a drug carrier, and many PEG hydrogels have been pro-
duced from aqueous solutions containing linear or branched
PEG macromolecules via chemical crosslinking. In addition
to hydrogels formed via radical crosslinking reactions, PEG
hydrogels have been formed, for example, via Michael-type
55 addition reactions upon mixing with thiol-bearing com-
pounds or via the reaction between amino-terminated poly
(ethylene glycol) and the herbal iridoid glycoside genipin. In
some cases, cell adhesive peptide domains or biodegradable
sequences have been introduced into PEG hydrogels to
60 endow them more biological signaling functions, including
the capacity for growth factor delivery. Accordingly, there
have been a variety of covalently crosslinked hydrogel sys-
tems developed to deliver growth factors via mechanisms
such as diffusion and chemical or enzymatic reaction.
65 Noncovalent interactions provide an alternative method for
crosslinking, as introduced above, removing the need for
toxic chemical crosslinking agents in gel preparation. In addi-
US 7,737,131 B2
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tion, noncovalent crosslinking strategies may offer advan-
tages in maintaining protein integrity and bioactivity until
delivery. Polymer hydrogels have been formed via specific
recognition events such as reversible antibody-antigen inter-
actions (see T. Miyata et al., A reversibly antigen-responsive
hydrogel, Nature 399 (6738) (1999) 766-769) and coiled-coil
interactions (see for example, C. Y. Xu et al., Reversible
hydrogels from self-assembling genetically engineered pro-
tein block copolymers, Biomacromolecules 6 (3) (2005)
1739-1749; C. Wang et al., Hybrid hydrogels assembled from
synthetic polymers and coiled-coil protein domains, Nature
397 (6718) (1999) 417-420; W. A. Petka, et al., Reversible
hydrogels from self-assembling artificial proteins, Science
281 (5375) (1998) 389-392). There has been little attention
given, however, to the interaction between peptides (particu-
larly coiled-coils) and polysaccharides in hydrogel assembly.
Further, the fabrication of biologically active fibers through
such functionalization strategies is a fairly new and unex-
plored area in the field of electrospinning, and electrospun
fibers have not been investigated for their ability to incorpo-
rate growth factor binding glycosaminoglycans, such as hep-
arin, in a manner designed to control release.
SUMMARY OF THE INVENTION
The invention is directed to a functionalized polymer
matrix comprising a matrix polymer, a compatibilizing poly-
mer and a small functioning molecule.
The invention is further directed to a method for formulat-
ing a functionalized matrix polymer comprising: functional-
izing a compatibilizing polymer with a small functioning
molecule and administering said functionalized compatibi-
lizing polymer into a matrix polymer.
The invention is also directed to a functionalized
crosslinked matrix comprising at least one functionalized
compatibilizing polymer capable of assembly.
The invention is additionally directed to a crosslinked
matrix that comprises the combination of a compatibilizing
polymer-biomolecule conjugate and a growth factor.
The invention is finally directed to a method for delivery of
a drug to an animal comprising: formation of a functionalized
polymer matrix comprising a matrix polymer, a compatibi-
lizing polymer and a drug; and administering said polymer
matrix to said animal.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a scanning electron micrograph of PEO/LMWH-
dye electrospun fibers.
FIG. 2 shows Laser Scanning Confocal Microscopy
(LSCM) images of electrospun PEO fibers (a) transmitted
light and (b) fluorescence (5 µm scale bar).
FIG. 3 is an LSCM image of electrospun PEO/LMWH-dye
fibers (5 µm scale bar).
FIG. 4 is a scanning electron micrograph of electrospun
PEO/PEG-LMWH-dye fibers.
FIG. 5 is an LSCM image of PEG-LMWH-dye/PEO elec-
trospun fibers (5 M scale bar). Dark and colored regions are
caused by folds in the surface of the macroscopic sample; not
by composition variations.
FIG. 6 shows scanning electron micrographs of (a) PLGA
electrospun fibers, (b) PLGA/LMWH-dye fibers, and (c)
PLGA/PEG-LMWH-dye fibers.
FIG. 7 shows LSCM images of electrospun PLGA fibers
(a) transmitted light and (b) fluorescence (10 µm scale bars).
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FIG. 8 shows LSCM images of electrospun (a) LMWH-
dye/PLGA fibers and (b) PEG-LMWH-dye/PGLA fibers and
(c) z-stack of PEG-LMWH/PLGA fibers (10 µm scale bars).
FIG. 9 shows bFGF binding on electrospun fibers. Eachbar
5 indicates ±standard deviation of the average of three measure-
ments.
FIG. 10 shows scanning electron microscopy images of
PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA
fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14
io days.
FIG. 11 shows retention of heparin within electrospun
matrices as observed by multiphoton microscopy for the
PEG-LMWH-dye/PLGA fibers and LMWH-dye/PLGA
fibers after incubation in PBS for 6 h, 1 day, 3 days, and 14
15 days (10 µm scale bars).
FIG. 12 shows retention of PEG-LMWH-dye within depth
of the electrospun matrix after 14 days of incubation in PBS
as imaged via multiphoton microscopy.
FIG. 13 depicts the release of bFGF from PLGA, LMWH-
2o Dye, and PEG-LMWH-Dye electrospun fibers after 5 h and
24 h incubation in PBS.
FIG. 14 is a digital picture displaying the visual differences
observed in the binding of bFGF to PLGA, LMWH-Dye, and
PEG-LMWH-Dye electrospun fibers after 5 h and 24 h incu-
25 bation in PBS.
FIG. 15 shows the results from the BrdU cell proliferation
assay. Each bar indicates±standard deviation of the average of
three measurements.
FIG. 16 provides LSCM images of (a) LMWH/PLGA and
30 (b) PEG-LMWH/PLGA fibers (blue) incubated for 8 days
with MG63 cells (green) (10 µm scale bars).
FIG. 17 shows (a) CD spectra of PEG-PF4ZIP at different
concentrations in PBS at 25° C.; (b) Concentration depen-
dence of the MRE for PEG-PF4ZIP at 222 nun. The solid line
35 is the best fit.
FIG. 18 is a schematic of the assembly of hydrogels from
solutions of the two polymer conjugates. The PF4ZIP is ren-
dered as an oligomerized coiled-coil, as its concentration
(200 µM) under these experimental conditions is two orders
40 of magnitude greater than the measured Kd value.
FIG. 19 depicts storage moduli (closed symbols) and loss
moduli (open symbols) of the PEG-LMWH/PEG-PF4ZIP
hydrogels for different molar ratios. The response of 2.5 wt %
of the PEG-LMWH (circles) is shown for comparison.
45 FIG. 20 shows plots of normalized storage moduli G'
(w-0.1 Hz) as a function of HBP(PF4ZIP, ATIII or HIP) to
LMWH. HIP and ATIII data are adapted from reference 12.
FIG. 21 is a comparison of storage moduli (closed sym-
bols) and loss moduli (open symbols) of the PEG-LMWH/
50 PEG-PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) obtained
25° C. and 37° C.
FIG. 22 shows shear recovery data for PEG-LMWH/PEG-
PF4ZIP hydrogels (LMWH:PF4ZIP=9:0.5) at 25° C. and 37°
C.
55 FIG. 23 depicts the bFGF release and hydrogel erosion
profiles of the PEG-LWMH/PEG-PF4ZIP hydrogel
(LMWH:PF4ZIP=8:1) and the PEG-LMWH/PEG-HIP
hydrogel (LMWH:HIP 8:2). The errors are derived from the
average of at least duplicate measurements.
60
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates generally to a composition
and method for the formation of functionalized polymer
65 matrices comprising a matrix polymer, a compatibilizing
polymer and a biomolecule or other small functionalizing
molecule. The invention is a novel strategy for the incorpo-
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ration of low molecular weight, biologically active molecules
(or molecules with other activities, e.g. sugars, peptides,
polysaccharides, polypeptides, dyes, electroactive groups,
etc.) into a fibrous or other matrix. The biological (or other)
molecules are conjugated to an intermediate molecular 5
weight polymer or "compatibilizing polymer" (e.g., but not
limited to: linear, star, hyperbranched) to allow retention of
the biomolecule in its bioactive form in fibers and other forms
of polymeric materials (e.g. films, gels, solids, particles, etc.).
Facile functionalization of electrospun fibers and other mate- io
rials with other low molecular weight, bioactive polysaccha-
rides and peptides (and other molecules) is contemplated by
this invention. Such functionalization is important because
biological processes are controlled via multiple and different
signaling molecules that have distinct spatial and temporal 15
release profiles, and the rate of their release from the fibers
can be controlled with the technology of this invention.
The invention is currently demonstrated in a preferred
embodiment comprising a low-molecular-weight-heparin
(LMWH)-modified star copolymer incorporated into electro- 20
spun fibers. Attachment of active molecules to intermediate
molecular weight polymers provides effective retention of the
molecules in the material over time scales relevant for bio-
logical and other potential applications. The choice of inter-
mediate molecular weight compatibilizing polymer will per- 25
mit control over retention and release rate of the molecule or
other active species.
Advantages of using a polymer-conjugated biomolecule
(i.e. polymer conjugate) for incorporation of bioactive moi-
eties into materials as provided by the invention, in place of 30
covalent attachment of the biomolecule to a high molecular
weight polymer used directly in material formation, are sev-
eral-fold. For instance, they include i) the use of a polymer
conjugate of the invention does not require a need for the
development of distinct chemistry relevant for a particular 35
molecule/polymer pair used in the material, as any polymer
conjugate could be incorporated into any polymeric matrix;
ii) the use of a polymer conjugate of the invention does not
limit the number of molecules that could be incorporated into
a given material for a given set of chemical transformations; 40
iii) in biological applications, the incorporation of biomol-
ecules via the current invention permits their controlled
release in soluble form; iv) it is easier to control release rate
and inclusion of multiple molecules at varying ratios/
amounts than when a bio (or other) molecule must be 45
covalently attached directly to the polymers of the material;
and v) the incorporation of biomolecules into materials via
this invention allows not only control over release rates, but
permits facile incorporation of multiple biological (or other
active) species into materials, and offers the potential for each 50
species to have a separate and distinct release rate.
The materials may find application in drug delivery or
tissue engineering scaffolds to promote tissue repair and/or
regeneration. They could be useful in other materials in
related applications where controlled release of a multiple of 55
active ingredients is desired, e.g. biosensors, detoxification,
DNA delivery, etc.
An important, overriding difference of the invention from
the prior art is that it allows for molecules (e.g. growth factors,
proteins, peptides, and other non-biological molecules, etc.) 60
to be incorporated into a polymer matrix via compatibiliza-
tion of the molecules with the polymer matrix, and that it
further allows for the controlled incorporation and release of
a variety of different molecules from a polymeric matrix. For
example, in the preferred embodiment (described in more 65
detail in example 1), the incorporation of heparin, and more
preferably LMWH, into an electrospun matrix via its attach-
8
ment to a star PEG polymer provides increased growth factor
binding to the electrospun matrix. The increased growth fac-
tor binding is due to the conjugation of LMWH to the PEG
molecule. The PEG-LMWH molecule takes longer to diffuse
out of the matrix, therefore allowing for more growth factor
binding to occur within a given time period as shown by
comparing the amount of growth factor binding to the PEG-
LMWH matrix versus a matrix consisting of LMWH alone
(See Example 1).
In the case of electrospun matrices, while there are limita-
tions to what polymers can be electrospun, there are many
possible uses. Solubility of fibers must be controlled, but such
control is also possible with this invention as well as matching
of mechanical properties for specific applications that are
accomplished using appropriate choice of polymer, additives,
and/or processing protocols.
Matrix Polymer
Matrix polymers, effective in this invention include but are
not limited to: Nylon 6,6; Nylon 6,10; (other nylons, also),
polyurethanes, polyacrylonitrile, polyvinyl alcohol, polylac-
tic acid, polyethylene-co-vinyl acetate, polycarbonate, poly
(iminocarbonate)s, polymethacrylates, poly(alkyl meth-
acrylic acid)s, polyacrylates, poly(alkyl acrylic acid)s, poly
(N,N'-diethylaminoethyl methacrylate), poly(N,N'-
dialkylaminoalkyl acrylamides), poly(heylene oxide)/PEO,
polyethylene terephthalate, polystyrene, polyvinyl chloride,
poly vinyl phenol, polyacrylamide, poly(N-alkyl acrylamide)
s, poly lactic-co-glycolic acids, polycaprolactone, poly(2-
hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene
fluoride), poly(vinylidene chloride), poly(ethylene glycol)/
PEG, polyvinyl pyrrolidone, polyethylene, polypropylene,
poly(3-hydroxybutyrate), poly(ortho esters), polyanhy-
drides, poly(ether-ester) azopolymers, poly(dimethyl silox-
ane), poly(phosphazene)s, other copolymers of the above
homopolymers (e.g. poly(methacrylic acid-co-ethylene gly-
col), and others.
Matrix polymers may also comprise natural polymers,
such as collagen, silk, silk-like protein polymers, elastin,
elastin-like protein polymers, poly(amino acids), cellulose
acetate, hyaluronic acid, chitosan, fibronectin, and others.
Composite materials comprising any of the above poly-
mers and an appropriate inorganic matrix (clays, silicates,
microparticles, etc.) can also be employed as a matrix poly-
mer for applications requiring high mechanical strength, such
as hard tissue engineering applications.
For drug delivery and biological applications, the follow-
ing are particularly preferred: Poly(ethylene), poly(propy-
lene), poly(vinyl chloride), poly(vinyl alcohol), poly(ethyl-
ene-vinyl acetate), poly(enol-ketone), poly(acrylic acids),
poly(acrylamides), poly(N-alkyl acrylamides), poly(alkyl
acrylates), PEG, PEO, poly(tetrafluoroethylene), poly(gly-
colic acid), poly(lactic acid), poly(lactic -co -glycolic acid),
poly(caprolactone), poly(3-hydroxybutyrate), poly(ortho
esters), poly(anhydrides), poly(amido amines), poly(ure-
thanes), poly(dimethyl siloxane), poly(phosphazenes),
among others. In addition, collagen, silk, silk-like protein
polymers, elastin, elastin-like protein polymers, poly(amino
acids), cellulose acetate, hyaluronic acid, chitosan, fibronec-
tin, and others, may also be used.
For applications in which a molecule is to be released in a
non-biological environment (e.g., water purification, agricul-
tural treatments, biosensors, smart fabrics, etc.), any of the
above polymers could be employed; specific polymers would
be chosen on the basis of the specific application.
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Compatibilizing Polymer
Any moderate molecular weight polymer, of the chemical
compositions of the above matrix polymers, that can be modi-
fied via reasonable chemical means with a biomolecule or
other small functional molecule, moiety, or particle is con-
sidered a compatibilizing polymer according to this inven-
tion. Moderate molecular weight preferably comprises, but is
not limited to, a molecular weight of approximately 1/2 to'/i000
the molecular weight of the matrix polymer it is bound to, in
such a range that the compatibilizing polymer permits homo-
geneous incorporation of the biomolecule into the matrix
polymer and sufficiently slows the diffusion-based release of
the biomolecule over timescales relevant for a particular
application. Some examples of moderate molecular weight
polymers that would function effectively as a compatibilizing
polymer in this invention include synthetic degradable poly-
mers such as poly(glycolic acid), poly(lactic acid), poly(eth-
ylene glycol) (PEG), poly(lactide-co-glycolide), and poly(e-
caprolactone) and others.
Additional polymers include polymers that could function
as the matrix polymer, such as: poly(acrylic acids), poly(acry-
lamides), poly(N-alkyl acrylamides), poly(alkyl acrylates),
poly(3-hydroxybutyrate), poly(ortho esters), poly(anhy-
drides), poly(amido amines), poly(urethanes), poly(dimethyl
siloxane), poly(phosphazenes), among others. In addition,
collagen, silk, silk-like protein polymers, elastin, elastin-like
protein polymers, poly(amino acids), cellulose acetate,
hyaluronic acid, chitosan, fibronectin, and others, may also be
used. As the compatibilizing polymer can be functionalized at
chemical groups located along the length of the polymer
chain or at the termini of the polymer, many polymers can be
employed. Potential additional polymers include: Nylon 6,6;
Nylon 6,10; (other nylons, also), polyurethanes, polyacry-
lonitrile, polyvinyl alcohol, polyethylene-co-vinyl acetate,
polycarbonate, poly(iminocarbonate)s, polymethacrylates,
poly(alkyl methacrylic acid)s, polyacrylates, poly(alkyl
acrylic acid)s, poly(N,N'-diethylaminoethyl methacrylate),
poly(N,N'-dialkylaminoalkyl acrylamides), polyethylene
terephthalate, polystyrene, polyvinyl chloride, poly vinyl
phenol, polyacrylamide, poly(N-alkyl acrylamide)s, poly(2-
hydroxyethyl methacrylate) (polyHEMA), poly(vinylidene
fluoride), poly(vinylidene chloride), polyvinyl pyrrolidone,
poly(3-hydroxybutyrate), polyanhydrides, poly(ether-ester)
azopolymers, poly(dimethyl siloxane), poly(phosphazene)s,
other copolymers of the above homopolymers (e.g. poly
(methacrylic acid-co-ethylene glycol), and others.
A preferred compatibilizing polymer for use in this inven-
tion is poly (ethylene glycol) or PEG. PEG is a linear or
branched neutral polyether with the chemical formula HO
(CH2CH2)n H. PEG is highly soluble in water and many
organic solvents (e.g., methylene chloride, ethanol, toluene,
acetone, and chloroform), and is readily available in various
sizes and functionalized architectures (e.g., amino-, car-
boxyl-, and sulfhydryl-terminated). Low-molecular weight
(<100 daltons) PEGS are viscous and colorless liquids,
whereas high-molecular weight PEGS are waxy solids whose
melting points are proportional to their molecular weights
with an upper limit near 67° C. PEG has been found to be
nontoxic and is approved by the FDA for use in drugs (paren-
tals, topicals, suppositories, nasal sprays), foods, and cosmet-
ics. Molecular weights of PEG used in biomedical applica-
tions usually range between a few hundred to 20,000 Da. The
molecular weight distribution of these PEG polymers is gen-
erally low, but the commonly used mono-methyl ethers of
PEG exhibit broader molecular weight distributions. In solu-
tion, PEG is also a highly hydrated polymer, where each
monomer (ethylene oxide unit) can bind three molecules of
water. PEG polymer exhibits a large degree of segmental
flexibility in aqueous solution and it is thought that PEG has
the ability to influence the structure of several molecular
layers of more loosely associated hydrating water molecules.
5 PEG is valued for its ability to exclude other polymers
(natural and synthetic) from its presence in aqueous environ-
ment. This exclusion of other polymers is the primary driving
force behind PEG's ability to reject proteins, from two-phase
systems with other synthetic polymers, and makes this poly-
10 mer both nonimmunogenic and nonantigenic. Because of its
many benefits, PEG is ideally suited for protein modification.
Indeed, PEG is currently considered one of the most success-
ful techniques to prolong the residence time of protein drugs
in the bloodstream. There are dozens of examples of PEG-
15 protein conjugates described in the literature. For example,
PEG has been considered a tool to enhance drug delivery to
neoplastic tissues such as, for instance, pegylated proteins
that have been applied in passive tumor-targeting while pegy-
lated monoclonal antibodies or MoAb fragments have been
20 investigated as immunotargeting agents. (see, for example
Sato H., Enzymatic procedure for site-specific pegylation of
proteins, ADVANCED DRUG DELIVERY REVIEWS 54
(4): 487-504 Jun. 17 2002; Deiters A., et al., Site-specific
PEGylation of proteins containing unnatural amino acids,
25 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
14 (23): 5743-5745 Dec. 6 2004; Hermanson, Greg T., Bio-
conjugate Techniques, I" edition, Academic Press, New
York, 1996) (All of which are herein incorporated by refer-
ence in their entirety).
30 PEG conjugation technology has been used, for example,
to improve the therapeutic efficacy of recombinant human
proteins because it alleviates many problems associated with
therapeutic protein formulations. For example, the attach-
ment of PEG to a protein affects its molecular size, charge,
35 and receptor-binding capabilities, which can serve to
decrease the conjugate's overall rate of clearance from the
body. Also, by sterically shielding the protein domains sus-
ceptible to proteolytic attack, PEG decreases the protein deg-
radation that causes protein biological inactivity. Finally, by
40 sterically masking a therapeutic protein's immunogenic/an-
tigenic determinants, PEG conjugation commonly results in
conjugates that are nonimmunogenic and nonantigenic. The
result of changes in the parental protein's characteristics by
PEG almost invariably increases the plasma half-life and
45 resistance to proteolytic degradation, and decreases immuno-
genicity and antigenicity of the resultant PEG-protein conju-
gate. Although PEG is generally considered to be non-immu-
nogenic, its parenteral administration has been found to
stimulate the production of antibodies.
50
Small Functioning Molecule
Small functioning molecules according to this invention
include, but are not limited to, biomolecules and functional
molecules such as peptides, sulfated peptides/polypeptides,
55 peptides/polypeptides with other functionalization/modifica-
tions, peptides/polypeptides containing non-natural amino
acids, polypeptides (natural AA, sulfated, non-natural AA,
other modified side chains, etc.), protein fragments, proteins
(e.g., growth factors, growth hormones, cytokines, insulin,
60 etc.), enzymes, saccharides, oligosaccharides, polysaccha-
rides, small molecule drugs (e.g., doxorubicin, aspirin, adria-
mycin, tetracycline (antibiotic), chloroquine (antimalarial),
tamoxifen, and other small molecule drugs that can be chemi-
cally conjugated to a polymer), dyes, organics, metals, and
65 nanoparticles and nanomolecules.
One particularly interesting biomolecule is heparin. Hep-
arin is a highly sulfated glycosaminoglycan that binds growth
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factors such as fibroblast growth factor (FGF), vascular
endothelial growth factor (VEGF), heparin-binding epider-
mal growth factor (HBEGF), transforming growth factor-(3
(TGF-(3), and others. Those having skill in the art are clearly
aware that growth factors are important for controlling cellu-
lar activities such as cell growth and proliferation. The incor-
poration of heparin in the electrospun matrix is of functional
importance owing to heparin's role as a binding site for many
growth factors; sulfated peptides may have similar activity
and would therefore also be useful for similar reasons. For
example, the binding of growth factors to glycosaminogly-
cans in the ECM is essential for storage, release, and preser-
vation of the bioactivity of the growth factor. Heparin prima-
rily serves to immobilize growth factors until release but is
also known to control their mitogenic activity, and in several
cases, serves as a cofactor to promote binding of the growth
factors to their receptors. Heparin is also known to regulate
the growth of fibroblast and endothelial cells when combined
with heparin-binding growth factors. For example, heparin
has been reported to have been incorporated into a chitosan
hydrogel where it was found to induce neovascularization in
vivo and enhanced the activity of acidic fibroblast growth
factor (aFGF) and basic fibroblast growth factor (bFGF) and
stabilized the growth factors in vitro. A variety of other
reports also confirm the benefits of including heparin in a bulk
hydrogel matrices, such as those comprising fibrin, PEG,
collagen, hyaluronic acid, and synthetic polymers, and the
extension to a fibrous matrix may provide additional struc-
tural advantages for producing materials that mimic the
ECM. Incorporation of biomolecules such as heparin, into a
polymer matrix allows for the exploitation of heparin's affin-
ity for growth factors as a strategy to deliver them from a
fibrous ECM-mimetic matrix. Those having skill in the art
understand that heparin binds variety of proteins with dispar-
ate function. It is contemplated that any such protein would be
candidates for use in this invention.
Method of Formulating Functionalized Polymers
Some methods for processing polymers into a given form
that can be applied in the invention for producing polymeric
matrices capable of controlled release of the compatibilizing
polymer/biomolecule conjugates include, for example,
crosslinking of a polymer to form a hydrogel network can be
employed; any method for crosslinking polymers can be
applied for formation of the crosslinked network, using stan-
dard initiators or at least trifunctional monomers; standard
free radical initiators include thermal initiators, redox initia-
tors, photoinitiators; the inclusion of a bifunctional vinyl
molecule with appropriate vinyl monomers would produce
crosslinked networks of the vinyl matrix polymers.
Additionally, noncovalent methods of producing a
crosslinked network could be employed. Such interactions
include but are not limited to ionic crosslinking (e.g. alginate
crosslinking via interaction with divalent cations, layer-by-
layer deposition of polyelectrolytes, etc.), protein-protein
interactions, peptide-saccharide interactions, saccharide-sac-
charide interactions, self-assembly of peptidic molecules,
and antibody-antigen interactions. The pore size of the
crosslinked network should be smaller than the size of the
compatibilizing polymer/biomolecule conjugate in order to
permit release of the biomolecule to be delayed via its con-
jugation to the compatibilizing polymer.
Any method of forming different three-dimensional par-
ticles and structures could also be applied in the current
invention. For example, emulsion (or inverse emulsion) poly-
merizations, crosslinking (in colloidal suspensions, micellar
or liposomal solutions, or emulsions), or spray crosslinking
can be used to form particulate and nanoparticulate polymers.
Crosslinking of monomer solutions in a mold or microfluidic
channel permits the construction of a matrix of essentially any
shape/size. Films cast of the monomer solutions (e.g., via
5 spincoating, doctor blade application, dipcoating, etc.) can
also be produced via crosslinking by any of the above mecha-
nisms or via simple casting/drying of a non-water soluble
polymer.
Electrostatic fiber spinning, or "electrospinning," is a pre-
io ferredprocess for this invention. Electrospinning is a process
by which superfine fibers, ranging from approximately 10
nanometers to about 10 microns in diameter, are formed. The
resulting electrospun fiber web has a high specific surface
area that is beneficial in a wide variety of technologies due to
15 the small fiber diameter and its porous structure. A high
voltage source is used during the electrospinning process to
generate an electrically charged jet of polymer solution or
melt expelled from a device such as a pipette. This process is
then followed by a drawing of the resulting filaments as they
20 solidify or coagulate. Electrospinning provides a simple
approach for production of solid, as well as hollow, one-
dimensional nanofibers from a variety of starting materials.
To date, dozens of synthetic or natural polymers, melts, and
polymer blends have been successfully spun using the elec-
25 trospinning process. (see, for example, Shin et al., Biomate-
rials 2003, 24, 4353-4364; Sukigara et al, Polymer 2003, 44,
5721-5727 (Frank Ko); Li et al, J. Biomed. Mater. Res. 2002,
60, 613-621 (Frank Ko); 7in et al., Biomacromolecules 2002,
3, 1233-1239 (David Kaplan); Tin et al., Biomaterials, 2004,
30 25, 1039-1047 (David Kaplan); Farach-Carson, M. C.; Wag-
ner, R. C.; Kiick, K. L., Extracellular Matrix: Structure,
Function, and Applications to Tissue Engineering, CRC Bio-
medical Engineering Handbook, CRC Press, New York,
2004; Huang et al., Composites Science and Technology
35 2003, 63, 2223-2253) (All said references are herein incor-
porated by reference in their entirety). A broad range of
electrospun materials have been published and include syn-
thetic polymers with electrical properties ranging from non-
conducting polyurethane to conducting polyaniline, in addi-
40 tion to natural polymers such as collagen and silkworm silk.
There is also much recent work on nanofibers electrospun
from biocompatible or biodegradable polymers for bioengi-
neering applications. The fibers may be made from a polymer
solution via an electro spinning process as described in
45 Reneker, U.S. Pat. No. 4,323,525, U.S. Pat. No. 4,689,525,
US 20030195611, US 20040018226, and US 20010045547,
which are incorporated herein by reference in their entirety.
The specific types of polymers that may be produced in fiber
form via the electrospinning process include those listed in
5o Huang, US 20030195611, US 20040037813, US
20040038014, US 20040018226, US20040013873, US
2003021792, US 20030215624, US 20030195611, US
20030168756, US 20030106294, US 20020175449,
US20020100725 and US20020084178 all of which are
55 herein incorporated by reference in their entirety.
When constructing electrospun fibers forbiomedical appli-
cations, certain material considerations must be acknowl-
edged. Some minimal properties of a drug delivery system are
that the material must be non-immunogenic, degradable with
6o non-toxic products, able to be excreted from the body, and
deliver therapeutic molecules in a controlled and predictable
manner. Manufacturing time and complexity, along with han-
dling, must also be considered. In compliance with these
requirements, matrix polymers such as PEO and PLGA serve
65 as excellent candidates for fabrication of the matrix via elec-
trospinning; indeed, the successful use of these polymers in a
variety of tissue engineering and drug delivery applications
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has been documented. Those having skill in the art are famil-
iar with the processes used in tissue engineering and drug
delivery as required for incorporation in this invention.
In addition to electrospinning, other traditional methods of
making polymeric fibers can be applied, when possible, to the
formation of active fibers of larger diameter. Given the choice
of biomolecule or functional molecule or particle with a par-
ticular matrix polymer would dictate the use of solution spin-
ning, melt spinning, or other spinning protocols.
Regarding the attachment of the biomolecule (or other
small functioning molecules) to the compatibilizing polymer,
the chemical reactions to be used are unlimited and are chosen
based on the desired compatibilizing polymer/biomolecule
combination. Initially, the matrix polymer composition may
be altered for any given desired application and the combi-
nations of matrix polymer/compatibilizing polymer/biomol-
ecule for any application are limited only by the choice of a
given application, not by the scope of the invention.
In a preferred embodiment, poly(ethylene glycol) (PEG)
functionalized with low molecular weight heparin (PEG-
LMWH), is fabricated into fibers for use in drug delivery,
tissue engineering, or wound repair applications. In particu-
lar, a four-arm star PEG with covalently attached LMWH was
found to be well suited for incorporation into electrospun
fibers with matrix polymers such as PEO and PLGA. Further,
the use of a PEG-LMWH conjugate proved to have a better
effect on growth factor binding than when compared to free
LMWH (see Example 1).
Interestingly, it was observed that the incorporation of
heparin into the electrospun PEO and PLGA fibers did not
affect the surface morphology or fiber diameters. The fibers
produced had diameters ranging from approximately 100 nm
to 400 mu. Our data indicates that PEG-LMWH conjugates
can be incorporated into an electrospun matrix at concentra-
tions ranging from 3.5 µg to 85 µg per milligram of electro-
spun fibers, although with greater heparin concentrations in
the spinning solution, it should be feasible to produce higher
levels of heparin loading in the fibers. Incorporation of PEG-
LMWH into the matrix permits retention of the heparin for at
least 14 days. Improvements in the binding of basic fibroblast
growth factor (bFGF) to the electrospun fibers were also
observed for fibers functionalized with PEG-LMWH over
those functionalized with LMWH alone. The combination of
these results suggests the utility for producing electrospun
fibers that are appropriately functionalized for use in bioma-
terials applications.
Although LMWH was indicated to be incorporated into
fibers with simple mixing in our investigation, the conjuga-
tion of LMWH to the star PEG slightly improved the amount
of heparin incorporated into the fiber matrix and permitted a
significantly improved amount of growth factor binding to
these matrices, which was suggested to result from an
improved retention of heparin in the fibers. If the use of such
PEG-LMWH conjugates also slows the release of heparin
over extended periods of time, it will allow for a slower, more
sustained release of growth factor, which is often required to
achieve desired biological outcomes.
The conjugation of heparin, and more preferably, LMWH,
to a relatively short (relative to the matrix polymer molecular
weight) polymeric chain therefore permits facile functional-
ization of fibers and also allows for retention and significantly
slowed release of LMWH from the matrix over time. Given
the importance of co-presentation of the LMWH with growth
factors at the growth factor receptor these systems also offer
the potential advantage of improving growth factor activity
over systems in which heparin is covalently attached directly
to the matrix and can therefore not be co-released with growth
factor. The rate of release of heparin (and therefore growth
factors) may also be modified via modifications in the poly-
mer conjugate's molecular weight over a wide range, and
coupled with the greater entanglement likely for flexible
5 polymer chains, this may offer advantages over simple incor-
poration of a higher molecular weight heparin in fibers. In
addition, the controlled incorporation and delivery of other
and potentially smaller bioactive molecules, such as peptides,
would also be widely possible via the incorporation of other
10 
similar PEG bioconjugates into these fibers. The ability to
simply mix various PEG-conjugates in the electrospinning
solution also offers advantages for creating multifunctional
fibers.
15 The PEG-LMWH molecules used in these electrospinning
studies have previously been demonstrated to be capable of
sequestering growth factors in hydrogels and delivering them
in bioactive form to induce proliferation of human umbilical
vein endothelial cells. The amount of LMWH in these elec-
20 trospun fiber matrices (3-86 µg) is also similar to that in
hydrogels produced with these polymers; the hydrogels can
effectively release bFGF for time periods of at least 16 days.
These results therefore show significant promise for the
potential of delivering similarly active growth factors from
25 electrospun matrices. The additional advantage of the ease of
mixing combinations of PEG-conjugates in the fibers is also
promising for the facile production of multifunctional, non-
immunogenic matrices for biomaterial applications.
It was found that LMWH functionalized PEG molecules
30 can be easily incorporated into electrospun fibers. These
fibers have nanometer scale diameters when electrospun
using either PEO or PLGA as carrier polymers. The amount
of LMWH per mg of fibers can range from 3.5-9.5 µg depend-
ing on the sample examined. Although both LMWH and
35 PEG-LMWH can be processed into fibers, the incorporation
of PEG-LMWH results in functional advantages such as
improved growth factor binding, resulting from improve-
ments in retention of the PEG-LMWH in the fibers over the
LMWH alone. The PEG-LMWH can be retained in the fibers
40 for at least 14 days, in contrast to LMWH, which is almost
completely released from the fibers after 24 hours. A slower
release of LMWH, and any coupled growth factors, allows for
drug delivery over a period of time that more closely matches
the time scales needed for tissue repair or regeneration should
45 the fibers be used in biomedical applications. The use of
electrospinning as the fabrication method for this biologically
functionalized matrix is preferred due to its ability to allow
for the incorporation of LMWH, ease of fabrication, fiber
spinning at a variety of temperatures, and use of small
50 amounts of material. The ability to scale electrospinning from
the laboratory to the industrial scale offers opportunities to
produce matrices for biomaterials applications. The electro-
spun matrix also meets many requirements in its porosity and
3-D nature to make the fibers suitable for drug targeting and
55 tissue engineering applications. Such simple strategies for
creating electrospun matrices that are both structurally rel-
evant and biologically active could find increased utility in a
variety of biomedical applications.
60 Functionalized Crosslinked Matrices
In an alternative embodiment, the invention is directed to
the use of a functionalized compatibilizing polymer in the
production of materials in which assembly, mechanical
response, and biological properties are controlled by protein-
65 polysaccharide interactions. Such materials are designed to
mimic the biological environment and find use in the delivery
of growth factors.
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Specifically, functionalized crosslinked matrices, such as
hydrogels, capable of assembly by, for example, interactions
between heparin and peptides, permit the formation of matri-
ces that allow for effective protein delivery. For example, an
elastic or vicoelastic hydrogel formed by the combination of 5
a compatibilizing polymer-LMWH conjugate and a compati-
bilizing polymer-peptide conjugate is a preferred interaction
contemplated herein. While the use of any compatibilizing
polymer is contemplated, a preferred compatibilizing poly-
mer for use in this embodiment would include PEG. Also, io
while preferred, it is not necessary that the compatibilizing
polymer be the same for both the LMWH conjugate and the
peptide conjugate.
In this particular embodiment, a hydrogel provides the
benefits of controlling drug delivery rates by, for example, 15
changing the heparin-binding peptide or manipulating the
hydrogel's physical properties and erosion profiles.
In a specifically preferred embodiment (more fully
described in Example 4) a heparin-binding, coiled coil pep-
tide, PF4ZIP1 was employed to mediate the assembly of hep- 20
arinized polymers. Heparin binding peptides (HBP) from
antithrombin III and the heparin interacting protein have also
been employed; any heparin-binding peptide with desired
affinities can be used in the production of materials of this
kind. Importantly, viscoelastic hydrogels were formed upon 25
the association of PF4ZIP-functionalized star poly(ethylene
glycol) (PEG-PF4ZIP) with low-molecular-weight heparin-
functionalized star PEG (PEG-LMWH). The viscoelastic
properties of the hydrogels can be altered via variations in the
ratio of LMWH to PF 4ZIP (or any HBP). Comparison of 30
growth factor (bFGF) release profiles with the hydrogel ero-
sion profiles indicates that bFGF delivery from this class of
hydrogels is mainly an erosion-controlled process and the
rates of bFGF release can be modulated via choice of HBP or
via variations in the mechanical properties of the hydrogels. 35
Manipulation of hydrogel physical properties and erosion
profiles provides novel materials for controlled growth factor
delivery and other biomedical applications.
Growth Factor-Crosslinked Matrices 	 40
In even another alternative embodiment, the invention is
directed to the use of a functionalized compatibilizing poly-
mer to form a crosslinked matrix that comprises the combi-
nation of a compatibilizing polymer-biomolecule conjugate
and a growth factor, wherein a biomolecule such as LMWH 45
functions effectively. In such an embodiment, it is intended
that the growth factor function as a cross link that eventually
is removed and drug is released. Removal of the growth factor
may result from passive release and/or targeted release via
targeted ligand exchange of the growth factor with specific 50
receptors on cell surfaces. The growth factor crosslink may
also itself be the desired drug, or in certain cases, the PEG-
LMWH polymer may have desired biological effect.
In a specifically preferred embodiment, PEG-LMWH can
be mixed with vascular endothelial growth factor (VEGF) to 55
form a viscoelastic hydrogel. Formation of a hydrogel occurs
as a result of the binding of the heparin-binding VEGF, with
multiple heparin binding sites, to the PEG-LMWH. While
VEGF, a dimeric growth factor with two heparin-binding
sites, is described, other methods for generating growth fac-
tors with multiple heparin binding sites could produce a
growth factor capable of crosslinking PEG-LMWH polymers
via noncovalent interactions (e.g. genetic mutation of growth
factor genes to introduce additional heparin-binding sites in
the growth factor, conjugation of multiple growth factors to a
polymer, etc.). Noncovalently crosslinked PEG-LMWH/
VEGF hydrogels are capable of releasing VEGF over periods
16
spanning at least two weeks, and the release of VEGF (and
resulting erosion of the network) is also responsive to the
presence of the cell surface receptors for VEGF. Release of
VEGF, and erosion of the network, can therefore be coupled
and made responsive to the cellular environment. VEGF
released from such assemblies causes increased proliferation
of porcine aortic endothelial (PAE) cells, which confirms that
the released VEGF is bioactive. Release of other growth
factors via similar mechanisms should therefore also be pos-
sible to permit release of multiple, bioactive growth factors.
Although the invention is illustrated and described herein
with reference to specific embodiments, the invention is not
intended to be limited to the details shown. Rather, various
modifications may be made in the details within the scope and
range of equivalents of the claims and without departing from
the invention.
EXAMPLES
Example 1
Electrospinning Functionalized Fibers
Materials and Methods
Hydroxy terminated and thiol terminated four-arm star
poly(ethylene glycol)s (Mn 10,300; Mw 11,300 g/mol and
M„=10,000; M_-10,800 g/mol, respectively) were pur-
chased from Polymer Source (Dorval, QC, Canada). LMWH
sodium salt (porcine intestinal mucosa, avg. molecular
weight 3000 g/mol) was obtained from Sigma (St. Louis,
Mo.). Alexa Fluor® 350 carboxylic acid, succinimidyl ester
was obtained from Molecular Probes (Eugene, Oreg.). Sol-
vents and reagents were distilled or purified according to
standard procedures.
Synthesis of PEG-LMWH Conjugate
N-Deacetylation of LMWH.
LMWH (M, 3000 g/mol) was used in these investigations.
In some cases, the LMWH was first separated into a high
affinity fraction via anionic exchange chromatography on
diethyl aminoethyl (DEAF) resin. Such fractionation is not an
absolute requirement, but provides a LMWH fraction with
higher heparin binding affinity. LMWH was eluted from the
column via gradient elution in Tris buffer (pH 7.5, 20 mM)
with sodium chloride concentrations ranging from 0 to 2M.
The late eluting fraction of LMWH was collected, dialyzed
against several changes of deionized water (SpectraPor,
MWCO 1000 Da), and lyophilized prior to use. The fraction-
ated LMWH (250 mg), hydrazine (5.3 g), hydrazine sulfate
(53 mg), and water (2.3 mL) were added to a heavy duty
reaction vessel, and the reaction vessel was tightly capped and
the mixture was stirred at 95° C. for 16 h. After the solvents
were removed in vacuo, the product was dialyzed using a
SpectraPor dialysis membrane (MWCO 1000 Da) first
against 1 M NaCl and finally against water (for each dialysis
bath was changed four times after 2, 8, 16, and 24 h) and
lyophilized to afford a slightly yellowish solid, 153 mg (61%
yield).
60 Synthesis of Maleimide and Alexa Fluor 3508 Functional-
ized LMWH.
To a 10 mL vial were added N-deacetylated heparin (10
mg), dry dowex 50WX4-200 ion-exchange resin (strongly
acidic cation), and anhydrous dimethylformamide (DMF, 4
65 mL) and the reaction mixture was stirred at room temperature
until complete dissolution of heparin was observed. The resin
was filtered and to the filtrate were added a few drops of
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anhydrous triethylamine and a solution of 4-(N-maleimidom-
ethyl)cyclohexanecarboxylic acid N-hydroxysuccinimide
ester (0.75 equiv.) (Sigma, St. Louis, Mo.) in anhydrous DMF
(0.3 mL) and the reaction mixture was stirred at 60° C. for 20
h. To this mixture was added a solution of Alexa Fluor 3508
carboxylic acid, succinimidyl ester (1 equiv.) in anhydrous
DMF and the reaction mixture was further stirred at 60° C. for
20 h. The solvent was removed in vacuo to yield a slightly
yellowish solid, which was redissolved in PBS (pH 6.5, 0.10
M, 0.15 M NaCI). After the insoluble particles were filtered,
the filtrate was purified via fast protein liquid chromatogra-
phy (FPLC) equipped with a Superdex 200 gel filtration col-
umn (Amersham, Piscataway, N.7.) using 0.2 M NaCl at 0.5
mL/min as eluting buffer. The heparin containing fractions
were combined and dialyzed using a SpectraPor membrane
(MWCO 1000 Da) first with 1 M NaCl and finally with water
(each dialysis bath was changed four times after 2, 8, 16, and
24 h) and were then lyophilized to give a slightly yellowish
solid, 4.2 mg; 'H NMR (400 MHz, D20, 29° C.): d-0.86-1.95
(10H, cyclohexyl, m), 3.38-5.43 (72H, heparin, m), and 6.84
ppm (2H, —COCH CHCO , s).
Synthesis of PEG-LMWH.
To a 100 mL round bottom flask equipped with a Nz inlet
were added maleimide and dye-functionalized LMWH (120
mg) and PBS (10 mL, pH 6.5, 0.10 M, 0.15 M NaCI) and the
solution was degassed by bubbling N2 for 15 min. To this
solution was slowly added a degassed solution of PBS con-
taining thiol terminated four-arm star PEG (65 mg in 10 mL)
and the reaction mixture was stirred at room temperature for
2 h. The reaction of the thiol was 96% complete as confirmed
via analysis with Ellman's reagent. The reaction mixture was
quenched by adding a solution of N-ethylmaleimide (12 mg)
in DMF (0.4 mL). The crude product was purified via FPLC
with a Superdex 200 gel filtration column (Amersham, Pis-
cataway, N.7.) at 0.5 mL/min using 0.2 M NaCl as eluting
buffer. Theproduct isolated by FPLC was purified via dialysis
against water (water bath was changed four times after 2, 8,
16, and 24 h) and lyophilized to give a slightly yellowish
solid, 150 mg; i H NMR (400 MHz, D 20, 29° C.): d-0.86-
1.95	 (40H,	 cyclohexyl,	 m),	 2.50-2.88	 (12H,
COCHzCHCO , m), 3.38-5.43 (288H, heparin, m), and
3.70 ppm (908H, PEG backbone, CH 2CH20 , s). Inte-
gration of the i H NMR spectrum suggests 73% functional-
ization of PEG with LMWH.
Electrospinning and Characterization
Fiber Spinning
The electrospinning apparatus consisted of a syringe pump
(Orion SageTM, Fisher, Fair Lawn, N.7.), high voltage supply
(Glassman Series EH, High Bridge, N.7.), 1 mL syringe (Pop-
per & Sons, New Hyde Park, N.Y.) and a needle (Hamilton,
Reno, Nev.) with an inner diameter of 0.51 mm. A voltage of
—12 kV was applied to the tip of the needle. A grounded metal
sheet was used as the target and was positioned 15 cm from
the tip of the needle for sample collection. The concentration
of the polymeric solutions varied depending on the carrier
polymer employed. PEO (BDH Chemicals, Poole, UK,
M_-300,000 g/mol) was used at a 10 wt % concentration in
water and a flow rate of 0.07 mL/min was employed. PLGA
(Sigma Aldrich, St. Louis, Mo., 75:25, M_-90,000-126,000
g/mol) solutions were made at a 45 wt % concentration in
DMF (Fisher, Fair Lawn, N.7.) andrequired a flow rate of 0.26
mL/hr.
Characterization
The electrospun fibers were characterized via field emis-
sion scanning electron microscopy (FESEM) (Hitachi
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S-4700) coupled with the energy dispersive X-ray (EDX)
(Oxford Inca X-Ray Microanalysis) for elemental analysis of
electrospun fibers. Laser scanning confocal microscopy,
LSCM, (Zeiss LSM 510 NLO) was used to observe the loca-
5 tion of the heparin-bound dye. A fluorescence excitation
wavelength of 747 mu and a KP685 filter were employed for
these experiments. An oil immersion type Plan-Neofluar 40x/
1.3 oil DIC (differential interference contrast) was used to
obtain images in FIGS. 4, 5, 9,10,12 and a Plan-Apochromat
10 63x/1.4 oil Ph3 (phase contract the 3 denotes a specific
condenser lens used) was used to collect the image in FIG. 7.
A z-series was made for each sample at 0.8 or 1.0 µm sections.
Toluidine Blue Assays
15 To determine the amount of heparin in the electrospun
fibers, a common colorimetric method employing toluidine
blue was used. A toluidine blue solution was made by dis-
solving 25 mg toluidine blue (Sigma Aldrich, St. Louis, Mo.)
20 and 1 g NaCl in 0.49 mL of 37% HCl and 50 mL of water. The
toluidine blue that reacts with the heparin is removed from
solution via extraction with hexanes (5 mL). The amount of
unextracted toluidine blue remaining in the aqueous solution
was determined by measuring the absorbance at 631 nm and,
25 by difference, provides an estimate of the heparin concentra-
tion.
Samples were prepared by adding 1 mg of electrospun
fibers to a solution consisting of 0.8 mL of toluidine blue
solution and 2.5 mL of 0.1 % NaCl. The test tube was vortexed
30 
and 5 mL of hexanes was added with additional vortexing.
After 10 minutes, 120 µL of the toluidine blue solution was
transferred into a cuvette and absorbance measurements were
taken. The control samples consisted of 1 mg of either PEO or
35 PLGA fibers, without heparin, to adjust for the amount of
toluidine blue that may adhere to the fibers. Measurements
were performed in duplicate.
Growth Factor Binding
40 Growth factor binding assays were employed to determine
if the LMWH and PEG-LMWH electrospun samples were
able to bind bFGF. All growth factor experiments were com-
pleted at room temperature in 24-well polystyrene assay
plates (Corning Inc., Corning, N.Y.), blocked with 3% bovine
45 serum albumin (BSA) (Sigma Aldrich, St. Louis, Mo.) in
phosphate buffered saline (PBS) (Invitrogen, Carlsbad,
Calif.). All electrospun samples were washed with PBS at
room temperature. Samples were placed in the wells and
incubated with 500 µL of a solution of basic fibroblast growth
50 factor (bFGF, R&D Systems, Minneapolis, Minn., 10 ng/mL
in PBS) for 2 h. After seven washes with 0.05 wt % Tween20
in PBS (PBS-T), 500 µL of a solution of bFGF antibody was
added (R&D Systems, Minneapolis, Minn., 2 µg/mL in PBS)
and incubated for 2 h. The samples were washed seven more
55 times with PBS-T. The samples were then incubated for 30
min. in a 500 µL solution consisting of 1 µL horseradish
peroxidase conjugated NeutrAvidin (Pierce, Rockford, Ill., 1
mg/mL), 8 mL PBS, and 2 mL SuperBlock TM Blocking
60 Buffer (Pierce, Rockford, Ill.). The fibers were then washed
seven times with PBS-T and incubated in 500 µL of TMB
substrate solution (Pierce, Rockford, Ill.) for 10-12 mins.
Absorbance at 450 nm was measured. All absorbance values
were normalized with respect to a well treated withbFGF and
65 antibody, as explained previously, but without any electro-
spun fibers. The growth factor binding assay was completed
three times and the average values are reported.
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Results
Electrospinning Physical Mixtures (1:4) of LMWH and PEO
A 1:4 LMWH to PEO mixture (25 mg LMWH and 100 mg
PEO) was dissolved in water and electrospun. The fibers
resembled typical electrospun PEO fibers with an approxi-
mate diameter of 100-400 nm and were slightly beaded. The
presence of microspheres with an average diameter of 1-5 M
was also observed. Two control solutions were made. One
control consisted of a 10 wt % PEO/H 20 and the other a 10
20
the sulfur indicates that LMWH is present, at low concentra-
tions, in the beaded areas of the electrospun mat. The micro-
spheres were shown to contain 73% C, 20% O, 4% Al, 1.2%
S, and 1.4% Na. The presence of sulfur and sodium imply that
LMWH is present in the microspheres at higher concentra-
tions than found in the beaded sections of the mat. The EDX
results are consistent with the expected composition of the
fibers, and the varying amount of sulfur in the different
regions suggests that LMWH is not uniformly incorporated
into the fibers via simple mixing.
TABLE 1
Average elemental composition of electrospun samples as determined by EDX
(compositions are represented in atomic weight percent)
Sample	 C (%)	 0(%)	 At (%)	 S(%)	 Na (%)
PEO Fibers 46 ± 14.7 5.0 ± 1.15 49 ± 14.2 ND* ND
LMWH Film 23 ± 1.63 40 ± 2.16 ND 17 ± 1.41 18 ± 2.50
1:4 LMWH:PEO
fiber section: 42 ± 9.02 5.0 ± 0.577 59 ± 18.9 ND ND
bead section: 61 ± 2.65 13 ± 2.31 26 ± 4.51 0.3 ± 0.025 ND
microsphere section: 73 ± 2.52 20 ± 5.13 4.0 ± 1.66 1.2 ± 0.48 1.4 ± 0.13
*ND = not detected
25
wt % LMWH/H2O. The 10 wt % PEO/H20 solution electro-
spun to form PEO fibers with a diameter of 100-400 mu. The
fibers were circular in their shape and contained beads (200-
600 mu in diameter) but no microspheres were observed. The
10 wt % LMWH/H 20 control did not form fibers or micro-
spheres, which is almost certainly due to the lack of entangle-
ments in the negatively charged LMWH (3,000 g/mol).
Attempts to electrospin higher MW heparin (12,000 g/mol)
also failed for similar reasons.
Toluidine blue assays were performed on the electrospun
physical mixtures of PEO and LMWH to determine if
LMWH was present in the sample. It was found that 86 ltg
(+/-7.15) of LMWH was present per mg of electrospun
fibers. The presence of LMWH indicated by the toluidine
blue assay is consistent with the presence of LMWH in the
matrix.
EDX was employed to determine the location of the hep-
arin in the fiber matrix via detection of sulfur on the sulfated
heparin; the results of the EDX analysis are outlined in Table
1. The presence of aluminum in the sample is due to the
aluminum SEM mount used to hold the fibers. PEO fibers
served as a control for this experiment; EDX detected 46% C,
5% 0, and 49% Al in the PEO fibers, consistent with the
composition of PEO. The significant amount of C detected
was most likely to due to carbon adhesive tab that was used to
secure the fibers for imaging. A thin film was cast of 10 wt %
LMWH/H20 and used as the second control The atomic
composition detected via EDX was 23% C, 40% O, 17% S,
and 18% Na, consistent with the presence of LMWH in the
sample (sodium is the counterion for the LMWH used in these
studies). The 1:4 LMWH:PEO electrospun sample was tested
in three different areas: the fiberportion, beadportion, and the
microsphere. The fibers contained 42% C, 5% 0, and 59% Al.
Since no sulfur or sodium was detected, the results suggest
that either the fiber section of the matrix consists of primarily
PEO or that the concentration of sulfur is too low for detection
via EDX. Generally, the lower limit of detection for EDX is
approximately 1%, so it is possible that the LMWH may be
incorporated into the fibers but at a concentration much lower
than 1%. The beaded section of the matrix was found to
contain 61% C, 13% O, 26%Al, and 0.3% S. The detection of
Electrospinning Dye-Labeled LMWH with PEO
To visually map the location of the LMWH throughout the
electrospun mat, a fluorescent dye, Alexa Fluor 3508, was
30 covalently attached to LMWH, and the fibers were analyzed
via LSCM; observation of fluorescence permits direct obser-
vation of the presence and location of LMWH throughout the
electrospun matrix. PEO (10 wt %) was mixed with Alexa
Fluor 3 50-labeled LMWH (0.2 wt %) and electrospun. FIG.1
35 shows resulting fibers with diameters of approximately 100-200 mu, with a few very large beads approximately 6 µm in
diameter.
The fibers were then analyzed via LSCM to determine if
the LMWH-dye molecules were incorporated into the matrix
40 and to determine their distribution in the matrix. Electrospun
PEO fibers were used as a control; results for the control are
shown in FIG. 2. FIG. 2a shows data in reflection mode and
confirms that fibers were present on the glass coverslip. FIG.
2b shows two small areas of fluorescence that are likely
45 impurities in the PEO or dust in the sample, but confirms the
complete lack of background fluorescence in the PEO fibers.
FIG. 3 presents LSCM data for electrospun fibers of the
LMWH-dye/PEO mixture. The results demonstrate the fluo-
rescence of the fibers, indicating the presence of LMWH. In
50 contrast to SEM and EDX results, the LSCM results also
suggest that the LMWH-dye is present not only in the beaded
sections of the matrix, but also in the fiber regions. FIG. 3
shows the fluorescence of the fibers due to LMWH-dye incor-
poration. Z-stack images were also taken (not shown) to
55 ensure that the LMWH-dye is present throughout the entire
depth of the matrix and is not localized in any one area. Due
to the LSCM limit of resolution, approximately 200 mu, the
exact location of the heparin within each individual fiber is
unknown. However, all LSCM images indicate that LMWH
60 is present throughout the depths of the electrospun matrix,
suggesting a fairly uniform dispersion of LMWH. Measure-
ment of LMWH via toluidine blue assay confirmed the pres-
ence of approximately 4.3 ltg (+/-0.923) of LMWH per mg of
electrospun sample. A direct comparison cannot be made
65 between the amount of LMWH in this sample and the amount
in the physical mixtures of LMWH and PEO due to differing
amounts of LMWH in the initial solutions. Nevertheless,
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these results suggest the opportunities for facile incorporation
of bioactive polysaccharides into electrospun matrices.
Incorporation of PEG-LMWH-dye in PEO for Electrospin-
ning
LMWH was covalently attached to the termini of a 4-arm
star PEG and evaluated for its incorporation into an electro-
spun matrix. PEG-LMWH-dye (0.2 wt %) was mixed with
PEO (10 wt %) in water. The electrospun fibers from this
solution were analyzed via FESEM, with results shown in
FIG. 6. As is shown in FIG. 6, the resulting fibers were
100-300 mu in diameter with the presence of microspheres
(1-3 µm). The morphology of the PEG-LMWH fibers was
very similar to those produced from the earlier samples with
free LMWH. In both electrospun mats, fibers are in the
nanometer size range and the onset of bead formation is
observed by the roughness of the fibers (see FIGS. 1 and 4).
The fiber matrix was then analyzed via LSCM to confirm
that the PEG-LMWH-dye molecule was incorporated in the
electrospun fibers; representative results are shown in FIG. 5.
Similar to the results in FIG. 3, the data shown here also
indicate that the fibers are evenly fluorescent across the
matrix, showing that the PEG-LMWH was evenly distributed
in the PEO fiber matrix. These fibers were found to contain
3.5 µg (+/-0.397) of heparin per mg of electrospun fibers.
These results indicate a slight improvement in LMWH incor-
poration in comparison to the LMWH/PEO fibers, and may
suggest that PEG-LMWH permits the incorporation of
slightly more heparin than in the fibers produced using free
heparin.
Changing the Matrix Polymer
Multiple polymers could be used as the matrix polymer.
PLGA was chosen as an alternate carrier polymer for the
LMWH systems due to the success of PLGA in biomaterial
applications. PLGA/DMF (45 wt %) was electrospun with
LMWH-dye (0.2 wt %) and also with PEG-LMWH-dye (0.2
wt %). Due to differences in molecular weight and viscosity,
the concentration of carrier polymer is different than those
used for PEO electro spinning, but all other processing con-
ditions remained the same. The electrospun PLGA fibers are
approximately 400-800 mu in diameter, (FIG. 6a). SEM
revealed that fiber morphology was not affected by the incor-
poration of LMWH-dye or PEG-LMWH-dye, (FIGS. 6b and
6c).
LSCM showed that the PLGA electrospun mat, shown in
FIG. 7a under transmitted light, does not fluoresce to any
significant extent. As encountered previously with PEO
fibers, there is a small area of fluorescence in FIG. 7b, which
is likely due to polymer impurities or dust on the sample. The
images shown in FIG. 8 reveal that both LMWH-dye and
PEG-LMWH-dye were incorporated into the PLGA matrix
and z-stack LSCM images confirm that the heparin is present
throughout the depths of the matrices. The toluidine blue
assay indicated that there is approximately 8.41 µg (+/-
0.532) of LMWH present per mg of electrospun LMWH/
PLGA sample. The PEG-LMWH/PLGA sample contained
9.50 µg (+/-0.382) of LMWH per mg of electrospun fibers.
The results of the FESEM, LSCM, and the toluidine blue
assays suggest that the carrier polymer can be changed with-
out affecting the incorporation of heparin or fiber morphol-
ogy.
Example 2
Growth Factor Release Assays of Elecrospun Fibers
An ELISA format was employed to characterize the bind-
ing of bFGF in a series of samples: a blank well, PLGA fibers
22
alone, LMWH/PLGA fibers, and PEG-LMWH/PLGA fibers.
Growth factor release studies were performed using a Quan-
tikine Human FGF Basic Kit (R&D Systems, Minneapolis,
Minn.). Incubation of the growth factor was completed using
5 a 24-well polystyrene plate (Corning Inc., Corning, N.Y.) and
transwell membranes (Fisher Scientific, Atlanta, Ga., 8 µm
pore size) were used to secure the fibers during the release
study. The plate, membranes, and fibers were blocked with
3% BSA (Sigma Aldrich, St. Louis, Mo.) in PBS (Invitrogen,
io Carlsbad, Calif.) overnight. All samples were washed three
times with PBS at room temperature and then incubated with
4 µL bFGF (R&D Systems, Minneapolis, Minn., 2.5 µg/mL in
PBS) for 2 h at 4° C. The fibers were then transferred to the
transwell membrane and I mL of PBS was added and incu-
15 bated at 4° C., unless otherwise indicated, for a specified
amount of time. The wells were replenished with fresh PBS
after each aliquot was removed. The amount of bFGF present
in the matrix was determined via use of a standard spectro-
photometric immunochemical assay following the protocols
20 of the manufacturer (R&D Systems, Minneapolis, Minn.).
Slight variations of the procedure could be necessary depend-
ing on the composition of the matrix.
The optical density measurements, at a wavelength of 450
mu, resulted in the following absorbance values relative to the
25 control (increasing absorbance values correlate with increas-
ing growth factor binding): PLGA fibers 1.59 (+1-0.055),
LMWH/PLGA fibers 2.46 (+/-0.146), and PEG-LMWH/
PLGA fibers 3.59 (+/-0.106). FIG. 9 shows that there are
significant differences in bFGF binding between the LMWH/
30 PLGA and PEG-LMWH/PLGA fibers, despite the fact that
the toluidine blue assays show that the two matrices contain
similar amounts of LMWH after electrospinning. Since both
the LMWH and PEG-LMWH samples began with similar
amounts of heparin but did not exhibit the same level of bFGF
35 binding, these data suggest that the PEG-LMWH may be
retained in the electrospun fibers more effectively than
LMWH alone. FESEM characterization of the electrospun
membranes after the growth factor binding assay revealed
that the PLGA fibers exhibited no visible signs of degradation
4o during the time frame of the growth factor binding study
(FIGS. 10, parts a and b). This observation corroborates the
fact that differences in growth factor binding likely result
from differential LMWH retention rather than from varia-
tions in fiber degradation between samples. These electro-
45 spun membranes were also incubated in PBS for an additional
I day, 3 days, and 14 days to determine if any fiber degrada-
tion occurred (FIG. 10, parts c-h). These SEM images show
that there are no visible signs of fiber degradation for the time
period studied in this investigation.
50 Characterization of the fibers after completion of the
growth factor binding assays was conducted via multiphoton
microscopy. FIG. 11, parts a and b, shows the LMWH reten-
tion within the electrospun fibers after the growth factor
assay, or 6 h of PBS incubation. After only 6 h in PBS, slight
55 differences in the amount of LMWH within the fibers were
observed via multiphoton microscopy; these differences were
much more pronounced with an additional 24 h incubation in
PBS (FIG. 11, parts c and d). In FIG. 11, parts e-h, the
multiphoton images are shown in fluorescence and reflection
60 mode. This was necessary due to the small amount of fluo-
rescence in the samples in order to prove that fibers are
present. In FIG. 11, parts g and h, the most visible differences
are observed. After 14 days incubation in PBS, the PEG-
LMWH-dye fibers still exhibit a moderate level of fluores-
65 cence in comparison to the LMWH-dye fibers, which show
minimal signs of fluorescence. The differences in the amount
of LMWH retained in the fibers were also observed through-
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out the depth of the matrix, as confirmed via z-stack images
(see FIG. 12 for a representative z-stack image of PEG-
LMWH-dye fibers after 14 days incubation in PBS).
bFGF release experiments were conducted with the 0.2
wt % LMWH-dye and PEG-LMWH-dye fibers over a 24 h
period. As seen in FIG. 13, the release of LMWH-dye, PEG-
LMWH-dye, and the PLGA control all exhibited less than 1 %
release of bFGF. This study was repeated to monitor the
release over a 21 day period, assuming that the low release
rates were due to the short incubation time of 24 h. However,
the 21 day release consistently showed less than 1% bFGF
release for all samples. Similar results were obtained in
release studies conducted at 37° C. In order to determine if
any bFGF remained in the electrospun matrices after these
release studies, a binding study was completed on the 0.2 wt
% heparin-containing fibers after 5 h and 24 h release in PBS.
FIG. 14 is a digital picture showing the visual differences in
the binding of bFGF to the fibers. The more intense the blue
color, the more bFGF present. This picture clearly shows
dramatic differences in binding to the PEG-LMWH fibers
versus LMWH and PLGA only fibers. However, more
LMWH is present in the PEG-LMWH-dye fibers. This sug-
gests that either 1) more bFGF is retained in the PEG-
LMWH-dye fibers due to the reduced diffusion times of the
PEG-LMWH-dye complex or 2) all fibers may contain simi-
lar amounts of residual bFGF but the PEG-LMWH-dye fibers
protect the structure of the bFGF and, thus, apparently more
growth factor is detected by the immunochemical assay.
Example 3
Cell Proliferation Assay
The PEG-LMWH/PLGA, LMWH/PLGA, and PLGA
fiber matrices were tested to determine if there were any
differences in the ability of the membranes to affect cellular
proliferation of MG63 (human osteosarcoma) cells. PLGA,
LMWH/PLGA, and PEG-LMWH/PLGA electrospun mem-
branes were sterilized under UV light for 4 h and incubated in
1.5 mL Dulbecco's Modified Eagle Medium (DMEM) con-
taining 5% (v/v) fetal calf serum (FCS), bFGF (10 ng/mL),
penicillin (100 U/mL) and streptomycin sulfate (100 µg/mL)
for 2 h. The membranes were then washed 2-3 times with
sterile PBS. All membranes were incubated in bFGF (15
ng/membrane) prior to the cell proliferation assay. The mem-
branes were then placed in 24-well tissue culture dishes con-
taining an MG63 cell (2x105 cells/mL, American Type Cul-
ture Collection, Manassas, Va.) suspension in DMEM
supplemented with 5% (v/v) FCS. The plates were shaken
every 30 min for 4 h. The scaffolds were then transferred to a
new 24-well plate and incubated in DMEM containing 1%
(v/v) FCS at 37° C. in an atmosphere of 95% air and 5% CO2.
Culture medium containing 1 % (v/v) FCS was changed every
3 days. Cultures were terminated on days 1, 3, 6, 9, 12, and 15.
MG63 proliferation was determined by immunodetection of
bromodeoxyuridine (BrdU) incorporation (Cell Proliferation
ELISA Biotrak System, Amersham Biosciences, Piscataway,
N.7.), according to the manufacturer's instructions. Cells
seeded on the electrospun membranes were labeled with
BrdU and then incubated with peroxidase-labeled anti-BrdU
antibody. Excess anti-BrdU antibody was removed by wash-
ing the membranes with washing buffer in a vortex mixer. The
membranes were then incubated in TMB substrate to produce
a colored solution. A plate reader was employed with detec-
tion at 450 nm to obtain optical density measurements. Three
fiber membranes per sample were tested each day.
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FIG. 15 illustrates the differences in cellular proliferation
on PLGA, LMWH/PLGA, and PEG-LMWH/PLGA mem-
branes. It was expected that cell proliferation would occur on
all the samples tested due to the biocompatibility of PLGA,
5 however, our interest was to determine which samples
reached maximum cell proliferation first. The most signifi-
cant differences were observed on day 6 where PEG-LMWH
membranes exhibit significantly higher cell proliferation and
therefore reached saturation before LMWH/PLGA or PLGA
io alone. FIG. 16 shows LSCM images of the cells (dyed green
using a syto 13 stain) on electrospun LMWH or PEG-LMWH
fibers (fluorescing blue due to the dye attached to the hep-
arin). FIG. 16b shows that more cells are present on the
PEG-LMWH/PLGA matrix and the image suggests that more
15 cells penetrate the PEG-LMWH matrix (FIG. 16b) when
compared to the LMWH fibers alone (FIG. 16a). These
images illustrate the differences in cellular proliferation due
to the presence of PEG-LMWH. Based on the results of this
cellular assay it is believed that PEG-LMWH increases the
20 rate of cell proliferation in comparison to the other samples
due to the retention of PEG-LMWH in the matrix that causes
increased retention and slower release of bFGF, which has
been suggested in previous results presented in FIG. 14. The
increased retention of bFGF may support higher cell prolif-
25 eration rates. Although this was a very preliminary cell study,
it does indicate that there are functional differences between
electrospun matrices functionalized with either PEG-LMWH
or LMWH alone.
30	 Example 4
Functionalized Cross-linked Matrices
Materials
35	 All materials were obtained and purified as described in
Example 1.
Methods
Synthesis of PEG-LMWH Conjugates
4o The synthesis of the PEG-LMWH conjugate exploited in
hydrogel assembly was conducted via Michael-type addition
reactions between maleimide functionalized heparin and
thiol -terminated four-arm star PEG, as described in Example
1. The degree of LMWH functionalization in PEG-LMWH
45 was determined to be 81% via 1H NMR spectroscopy. Syn-
thesis of PEG-LMWH-Alexa Fluor 350 was conducted via
similar protocols as previously described in the art.
Synthesis of PEG-HBP Conjugates
50 All HBPs were prepared on Rink Amide MBHA resin via
solid phase peptide synthesis with Fmoc-protection using a
PTI PS3 peptide synthesizer (Protein Technologies Inc, Tuc-
son, Ariz.) and purified via preparative-scale reverse-phase
HPLC. The PF4ZIP sequence CGGRMKQLED-
55 KVKKLLKKNYHLENEVARLKKLVG is based on a GCN4
coiled coil and mimics the heparin-binding domain of human
platelet factor 4. The heparin-binding peptides, ATIII and
HIP, from antithrombin III (ATIII) and heparin interacting
protein (HIP), have sequences of CKbAFAKLAARLYRKA
6o and CRPKAKAKAKAKDQTK, respectively. Any heparin-
binding peptide of sufficient affinity and appropriately slow
dissociation (from heparin) would be equally applicable for
use in these hydrogels. Peptides isolated as single fractions
via HPLC were characterized via MALDI and ESI mass
65 spectrometry. The mass of the purified HBPs was confirmed
via ESI mass spectrometry. For example, for PF4ZIP1
m/z=992.5 [(M+4H)4+, calc'd 992.0] and m/z1322.9 [(M+
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3H)3+, calc'd 1322.7]. Similar agreement between theoreti-
cal and observed mass values was observed for all other
HBPs.
The synthesis of the PEG-HBP conjugates utilized in
hydrogel assembly was conducted via Michael addition reac-
tions between vinyl sulfone-terminated four-arm PEG and
cysteine-terminated PF4ZIP peptide.
Characterization
Peptides, PEG-LMWH, and PEG-HBPs were character-
izedvia 1 H NMR spectroscopy and MALDI-TOF Mass Spec-
trometry to determine purity, composition, and degree of
functionalization.
Circular Dichroic Spectroscopy (CD)
CD spectra were measured at 5° C. to 75° C. on a 7asco
7-810 spectropolarimeter (7asco Inc, Easton, Md.) equipped
with a 7asco PTC-424S temperature controller. Samples were
equilibrated at the desired temperature for 30 minutes prior to
data collection; equilibration was indicated by the absence of
further changes in the CD signal at longer equilibration times.
All CD spectra were taken in a 1 mm pathlength quartz
cuvette, at wavelengths from 200 to 250 mu. Data points were
recorded at every nanometer with a 4.0 s response time. The
concentrations of peptide samples were determined via
amino acid analysis for calculation of mean residue elliptici-
ties.
Heparin Affinity Measurements
Heparin-sepharose affinity liquid chromatography was
performed on an AKTA Explorer FPLC equipped with a
HiTrap Heparin HP column (5 ml, -10 mg heparin/ml gel,
Amersham Biosciences Corp, Piscataway, N.7.). Surface
Plasmon Resonance (SPR). SPR sensorgrams were recorded
on a BiaCore 3000 instrument (Biacore Inc, Piscataway,
N.7.), employing a high-capacity LMWH surface created on
a commercially available streptavidin-coated chip via treat-
ment with biotinylated LMWH.
Bulk Rheology Experiments
Bulk rheology experiments of the PEG-LMWH/PEG-
HBP hydrogels were conducted at 25 or 37° C. on a stress-
controlled rheometer (MCR 500, Paar Physica, Anton-Paar,
Ashland, Va.) with a 25.0 mm diameter parallel plate geom-
etry and a 1 mm gap distance. Strain sweeps were performed
on samples from 0.001% to a maximum strain of 100% to
determine the limit of the linear viscoelastic regime (LVE). At
a constant strain of 0.1%, chosen from the LVE, frequency
sweeps ranging from 0.1 Hz to 100 Hz were conducted. Shear
recovery experiments were also performed for the PEG-
PF4ZIP-containing hydrogels, and prior to these experiments,
a baseline oscillation at a constant strain of 0.1% and a con-
stant frequency of 10 Hz was performed, followed by a high-
speed rotation with a 1000 s-1 shear rate for 10 s. The recov-
ery was then measured with a time sweep experiment at a
constant strain of 0.1% and a constant frequency of 10 Hz.
Fluorimetry Experiments
Fluorimetry experiments to measure the concentration of
PEG-LMWH-Alexa Fluor 350 (in eroded solutions of PEG-
PF4ZIP-containing hydrogels) were performed using a Fluo-
roMax-3 spectrofluorometer (7obin Yvon Inc, Edison, N.7.)
with a xenon arc lamp illuminater. Erosion of PEG-LMWH
from other PEG-HBP-containing hydrogels was determined
gravimetrically. 45 µL of each sample were loaded into a
cuvette and excited at 346 mu, the excitation spectra peak
value ofAlexa Fluor 350. The emission spectra peak value at
442 nmwas recorded. Solutions of PEG-LMWH-Alexa Fluor
350 in PBS, with concentrations from 5.42x10-4 wt % to
26
4.23x10-6 wt %, were employed for generation of the stan-
dard curve. For erosion profile experiments, the PEG-
LMWH-Alexa Fluor 350 was premixed with the PEG-
LMWH at a weight ratio of 1:158. The fluorescence
5 intensities of the PEG-LMWH-Alexa Fluor 350 in the eroded
PEG-LMWH were then measured and permitted calculation
of the percentage of PEG-LMWH eroded from the hydrogels
in hydrogel erosion experiments.
10 Assembly of PEG-LMWH/PEG-HBP (and PEG-LMWH/
GF) Hydrogels
The PEG-LMWH/PEG-HBP hydrogels were formed by
the interaction between LMWH andPF4ZIP. 5 wt% solutions
of the PEG-HBP in PBS were added directly to 2.5 wt %
15 solutions of the PEG-LMWH in PBS, to afford hydrogel
networks at a final composition of 2.5 wt % total polymer. The
solutions were mixed in ligand mole ratios of 9:0.5, 8:1, and
7.5:2.5 (LMWH:PF4ZIP dimer); other ligand mole ratios are
also useful for hydrogel assembly. For VEGF-crosslinked
20 hydrogels, an 8 wt % solution of PEG-LMWH in PBS is
mixed with varying amounts of solid VEGF (0.1-20 µg) to
afford a self-supporting gel upon sufficient addition of VEGF.
After mixing, the hydrogels were stored at 4° C. The stored
hydrogels were equilibrated to room temperature prior to
25 rheological characterization (typically several minutes).
bFGF Release and Hydrogel Erosion Experiments
bFGF release and hydrogel erosion experiments were per-
formed at 4° C. in 24-well polystyrene assay plates (Corning
30 Inc., Corning, N.Y.), blocked with PBS containing 5% BSA
and 0.05% Tween 20 (Sigma, St. Louis, Mo.). The wells were
aspirated and washed 4 times with 0.05% Tween 20 in PBS
before loading samples. Afterward, 200 µL hydrogel was
placed on the bottom of each well and 2.8 mL PBS was added
35 carefully over each gel. 1 mL PBS was taken out of the well
at 1, 2, 6 and 24 h and then each following day, followed by
replacement with 1 mL fresh PBS. The amount of bFGF in
each sample was measured with a bFGF Quantikine kit (R&D
Systems, Minneapolis, Minn.). Thehydrogel erosionkinetics
40 were conducted on the same samples used for bFGF release
experiments.
Results
Oligomerization of PF4ZIP
45 Our initial studies were aimed at determining the oligomer-
ization properties of the coiled-coil PF 4ZIP, as such informa-
tion is relevant to the subsequent use of the PF 4ZIP in hydro-
gel formation. No such characterization was necessary for the
other HBPs, as they do not form higher-order assemblies.
50 Circular dichroic spectroscopy studies were conducted to
assess the folding of the PF4ZIP under various conditions.
Solutions of PF 4ZIP dissolved in PBS were scanned from 250
mn to 200 mn at varying temperatures between 5° C. and 75°
C. The CD spectra of PF4ZIP at a variety of temperatures
55 show an isodichroic point at 203 mu, validating the existence
of a two-state equilibrium. At temperatures below 55° C., the
spectra observed exhibit two minima at 208 mn and 222 mu,
demonstrating that PF4ZIP exists in the coiled-coil state
under conditions of interest for hydrogel applications. As
60 seen by the appearance of a single minimum at 203 mn in the
data collected at elevated temperatures, the structure of
PF4ZIP reversibly changes to random coil at elevated tem-
perature. Maximum mean residue ellipticity values at 222 mn
(MRE222) were measured to be -30,470 deg cm 2 dmol-i for
65 the PF4ZIP at 15' C., consistent with reported values ranging
from -25,000 to -35,000 deg cm 2 dmol-i for various GCN4
-mimic peptides in PBS at 15° C.
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The conformation of PF4ZIP at various concentrations was
also monitored via CD. At all measured concentrations, the
spectra observed exhibit two minima at 208 nun and 222 mu,
demonstrating the helical character of PF4ZIP under these
conditions. The measured MRE222 for a solution of 56 µM
PF4ZIP in PBS is —24,580 deg cm2 dmol-1 , which is consis-
tent with the value reported for 40-60 µM PF 4ZIP in 3 mM
sodium citrate buffer (-27,000 deg cm 2 dmol-i). The differ-
ence between the measured ellipticity and the ellipticity of the
unfolded monomer is related to concentration and can be fit to
determine the Kd of the dimerization, via standard fitting
procedures well-described in the literature. The calculated
equilibrium constant of unfolding, Kd, is 3.48±0.03 µM.
Solutions of PF4ZIP attached to star-PEG were also studied
via CD, to ensure that conjugation to PEG did not signifi-
cantly alter the association of the PF4ZIP coiled-coils. As
shown in FIG. 17(a), the spectra of PEG-PF4ZIP are essen-
tially identical to the spectra obtained for the isolated PF4ZIP.
Slight differences in MRE values likely arise from uncertain-
ties in the precise peptide concentrations for the PEG-PF4ZIP
samples. The Kd value derived from the best fit of the con-
centration dependence of (FIG. 17(b)) for PEG-PF4ZIP is
0.93 µM. The PF 4ZIP concentrations during NMR character-
ization and hydrogel formation and characterization are
always much greater than these measured Kd values (e.g., 200
µM and higher), suggesting that PF4ZIP will exist as a fully
folded dimer under those conditions.
Heparin-binding Affinity
Our previous investigations of PEG-LMWH/PEG-HBP
hydrogels suggested that the viscoelastic properties of the
noncovalently assembled hydrogels were related to the hep-
arin-binding kinetics and affinities of the peptides (from anti-
thrombin III (ATIII) or heparin interacting protein (HIP)).
Heparin-sepharose affinity chromatography and SPR experi-
ments were therefore used to compare the heparin-binding
affinity of the various HBPs. Results of these experiments are
summarized in Table 2.
TABLE 2
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(962±10 mM) is higher than that measured for the ATIII
peptide (594±2 mM) and for the HIP peptide (687±1 mM),
indicating that PF4ZIP has higher heparin-binding affinity
than the ATIII and HIP peptides and should therefore be
5 competent for hydrogel assembly. These results are consis-
tent with previous reports indicating that similarly high con-
centrations of NaCl were required to elute 125I-labelled
PF4ZIP bound to a heparin-sepharose column in 0.02 M
Tris-HCl buffer pH 7.0 containing 0.05 M NaCl.
10 In SPR experiments, the interaction of the peptides with a
LMWH-modified SA chip surface was determined under
conditions described in the experimental section. Neither
nonspecific binding of heparin-binding proteins to SA chips
15 nor chip instability was observed in any of the SPR measure-
ments. In addition, no mass transport limitation or linked
reactions were indicated. The measured association of the
PF4ZIP with LMWH proceeds with a rate constant of
2.24±0.05x105 M-1 s i,whilethedissociationproceedswith
a rate constant of 2.56±0.10x10-3 s-i , yielding a KD of
20 approximately 1.15±0.03x10-2 µM. These faster association
kinetics, relative to those reported for the ATIII and HIP
(Table 2) (see also N. Yamaguchi, B. S. Chae, L. Zhang, K. L.
Kiick, E. M. Furst, Rheological characterization ofpolysac-
charide poly(ethylene glycol) star copolymer hydrogels,
25 Biomacromolecules 6 (4) (2005) 1931-1940) are the primary
cause of the lower measured KD values for PF4ZIP-LMWH
binding, and the trend of the dissociation constants is consis-
tent with the chromatography results. The more rapid asso-
ciation rate, coupled with the similar dissociation rate, of30 PF4ZIP versus the other HBPs, points to the successful for-
mation of hydrogels between PEG-PF4ZIP and PEG-
LMWH. The measured KD of the binding between PF4ZIP
and LMWH is lower than the measured Kd of dissociation of
35 the coiled-coil obtained from CD experiments, which may
suggest that the LMWH-functionalized surface facilitates
coiled-coil formation. Nevertheless, the equilibrium con-
stants of dissociation determined via both methods are sub-
Heparin binding affinity data (at 25° C.) for heparin-binding peptides determined via
affinity chromatography and SPR. The errors are derived from the average of duplicate
measurements
Salt
required for
elution from
heparin
column
Peptide	 (MM)	 ka (M 's ')	 ka (S-1)	 KD (PM)
ATIII'	 594±2	 1.56±0.06x102 2.00±0.3x10 -3 	12.9±1.3
HIP'	 687 ± 1	 1.10 ± 0.08 x 10 3 4.64 ± 0.02 x 10-3	 4.20 ± 0.3
PF4z1p	 962 ± 10 2.24 ± 0.05 x 10 5 2.56 ± 0.10 x 10-3	 1.15 ± 0.03 x 10-2
'Data from previously reported studies (N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiick,
E. M. Furst, Rheological characterization of polysaccharide-poly(ethylene glycol) star
copolymer hydrogels, Biomacromolecules 6 (4) (2005) 1931-1940)
For heparin affinity chromatography experiments, HBPs
were loaded onto a heparin-sepharose column, and then
eluted with buffer of increasing NaCl concentration. The
concentration of NaCl required for peptide elution is used as
an indication of the affinity of the peptide for heparin. The
elution of the peptides from the heparin-sepharose column
required a salt concentration of 962±10 mM for the PF4ZIP
peptide. The salt concentration required to elute PF4ZIP
60 stantially lower than the concentrations employed during
hydrogel formation experiments (see below).
Temperature Dependence of PF 4ZIP Binding
65 The heparin-binding kinetics between LMWH and PF4ZIP
were monitored via SPR at several temperatures between 5°
C. and 37° C., to determine potential changes in binding
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kinetics that might alter hydrogel properties under physi-
ological conditions. Data from these experiments are shown
in Table 3.
TABLE 3
Heparin-binding affinity data for PF4ZIP at different temperatures, as
determined via SPR. The errors are derived from the average of duplicate
Tempera-
ture
	C C.)
	
k (M-is 1 )	 "'(S-1)	 KD (!M)
	
5	 1.56±0.01x105 3.74±0.17x10 -3 	2.41±0.10x10-8
	
15	 1.90 ± 0.04 x 105 1.67 ± 0.03 x 10-3	 8.82 ± 0.02 x 10-g
	
25	 2.24 ± 0.05 x 10 5 2.56 ± 0.10 x 10-3	 1.15 ± 0.03 x 10-8
	
37	 5.11±0.02x105 2.44±0.08x10-3 	4.78±0.14x10-g
The measured on and off rates fluctuate only slightly
throughout the temperature range, suggesting that nonco-
valently assembled hydrogels based on PF4ZIP and LMWH
interactions should exhibit consistent mechanical properties
at these temperatures.
PEG-LMWH/PEG-HBP Hydrogel Formation
Via i H NMR spectroscopy, functionalization of the star
PEG with HBPs was determined to be at least 59%, indicating
that PEG-HBPs meet the functional requirement (at least one
binding partner exhibits f>2) for crosslinking a hydrogel
upon interaction with PEG-LMWH (which showed a func-
tionalization of 81%, as determined via NMR). (see N.
Yamaguchi, K. L. Kiick, Polysaccharide poly (ethylene gly-
col) star copolymers as scalblds for the production of bioac-
tive hydrogels, Biomacromolecules 6 (4) (2005) 1921-1930;
and N. Yamaguchi, B. S. Chae, L. Zhang, K. L. Kiick, E. M.
Furst, Rheological characterization of polysaccharidepoly
(ethylene glycol) star copolymer hydrogels, Biomacromol-
ecules 6 (4) (2005) 1931-1940).
Accordingly, solutions of the two polymer conjugates in
PBS (2.5 wt % of the PEG-LMWH and 5 wt % of the PEG-
HBP) were mixed at various ligand molar ratios to form
hydrogels. Ligand molar ratios of 9:0.5 and 7.5:2.5 (LMWH:
PF4ZIP) were used to yield the PEG-LMWH/PEG-PF4ZIP
hydrogels. Similar ratios were used for the formation of func-
tionalized crosslinked matrices from mixtures of PEG-
LMWH with either PEG-ATIII or PEG-HIP, and any PEG-
HBP conjugate should be useful in a similar manner. The
application of such ratios was employed to maximize the
excess LMWH available for growth factor binding (see
below). Before addition of PEG-PF 4ZIP, the 2.5 wt % of the
PEG-LMWH was uniform and translucent. In addition, the
water-like viscosity of the PEG-PF4ZIP solution indicated
that there was no significant crosslinking of the peptide-
terminated star polymers via intermolecular coiled-coil for-
mation, although some oligomers of the PEG-PF 4ZIP bio-
conjugates may exist in solution. The formation of self-
supporting, opaque gels was immediately apparent upon
mixing the two polymer solutions. A schematic of the assem-
bly of the hydrogels is shown in FIG. 18. This assembly is
operative regardless of the identity of the PEG-HBP.
Bulk Rheology
The mechanical properties of the PEG-HBP containing
hydrogels were characterized via theological frequency
sweep experiments on bulk samples. The frequency sweep
results for PEG-LMWH/PEG-PF 4ZIP hydrogels (FIG. 19)
show that the storage modulus G'(w) is significantly larger
than the loss modulus G"(w) over all measured frequencies
and G'(w) exhibits a pronounced plateau extending to fre-
30
quencies of tens of reciprocal seconds, indicating a viscoelas-
tic gel. Essentially identical results are obtained regardless of
the identity of the PEG-HBP. The magnitude of G'(w) and
G"(w) also increases as the molar ratio of the peptide com-
5 ponent is raised. The average G'(w) increases from an average
value of 70 Pa for PEG-LMWH to approximately 80 and 180
Pa for hydrogels with molar ratios of LMWH to PF4ZIP of
9:0.5 and 7.5:2.5, respectively. The average G"(w) also
increases monotonically with higher molar ratio of the pep-
10 tide component, from less than 10 Pa for PEG-LMWH to
more than 30 Pa for hydrogels with molar ratios of LMWH to
PF4ZIP of 7.5:2.5. Bulk theology experiments were also
performed on the samples at various gap heights of I mm, 0.5
mm, and 0.25 mm. At frequencies from 0.1 to 63 Hz, the
15 observed identical dynamic moduli at different gap heights
indicate that no significant slipping occurs in that frequency
range.
The strengthening effects on storage modulus upon addi-
tion of PEG-HBP to PEG-LMWH are presented in FIG. 20
20 for G' (w=0.1 Hz) plotted as a function of the ratio of HBP to
LMWH in the samples, with moduli normalized by the initial
storage modulus of PEG-LMWH. The plateau in the modulus
with increasing PF 4ZIP or HIP concentration may imply that
the HBP-binding sites on LMWH have been saturated. The
25 increase in the elastic modulus upon addition of PEG-PF4ZIP
for the PEG-LMWH/PEG-PF 4ZIP hydrogels is lower than
that observed with addition of PEG-HBP for the PEG-
LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP hydro-
gels. Literature reports suggest that at least 4 tetrasaccharides
30 (16 units) are required for efficient heparin-PF4 protein inter-
actions, while HIP- andATIII-binding sites are believed to be
similar pentasaccharides in heparin. The fewer PF 4 binding
sites on LMWH could lead to the lower storage modulus
plateau value and lower slope in FIG. 20 for the PEG-
35 LMWH/PEG-PF4ZIP hydrogels than that observed for the
PEG-LMWH/PEG-ATIII or the PEG-LMWH/PEG-HIP
hydrogels. These results indicate two things. First, the
mechanical properties of the hydrogels are initially estab-
lishedby the self-interaction/assembly of PEG-LMWH. Sec-
40 ond, the dependence of storage modulus on HBP:LMWH
ratio clearly indicates that the PEG-HBPs mediate crosslink-
ing of the networks and that the interactions between HBP
and LMWH modulate the mechanical properties of the matri-
ces.
45 A similar dependence of theological properties on the con-
centration of heparin-binding crosslinker was observed for
PEG-LMWH crosslinked with VEGF. Laser tweezer
microrheology experiments, in this case, confirmed the elas-
tic behavior of the hydrogels at low and moderate frequen-
50 cies, and also demonstrated that the development of elastic
properties of the network are dependent on the concentration
of VEGF present in the network. Microrheology character-
ization was conducted on 4 wt % hydrogels in order to reduce
the elastic modulus sufficiently for measurement. 8 wt %
55 hydrogels provide improved mechanical properties, although
a variety of concentrations could be used depending on the
desired application.
The theological properties of the PEG-LMWH/PEG-
PF4ZIP hydrogels were also investigated at physiological
60 temperature. The mechanical properties of the hydrogels with
molar ratios of LMWH to PF 4ZIP of 9:0.5 and 7.5:2.5 were
examined. The frequency sweep data for the hydrogel
(LMWH:PF4ZIP=9:0.5) are presented in FIG. 21. The
moduli at 25° C. or 37° C. are essentially identical, with an
65 identical frequency dependence, although the gels at 37° C.
exhibit slightly lower loss moduli at higher frequencies. The
materials are therefore also elastic hydrogels at 37° C., in
US 7,737,131 B2
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corroboration of the SPR studies. This lack of temperature
dependence is also observed in the hydrogel with higher
PF4ZIP content, reflecting the temperature insensitivity of
both the PF4-LMWH interactions and the LMWH-LMWH
interactions.
Shear recovery data for the PEG-LMWH/PEG-PF4ZIP
hydrogels are exhibited in FIG. 22. Both the extent and time-
dependence of recovery were determined in these experi-
ments. FIG. 22 indicates that after the hydrogels are subjected
to a steady shear rate as high as 1000 s -i , they essentially
immediately recover their elastic properties, so only a slight
reduction in modulus can be measured. In addition, the
moduli at 25° C. and 37° C. are equal, with a matching
kinetics of recovery. The data are consistent with previous
theological frequency sweep studies (FIG. 21). The immedi-
ate recovery and stability of the PEG-LMWH/PEG-PF4ZIP
hydrogels even after subjected to high shear suggests their
potential utility in injectable applications.
Growth Factor Release and Hydrogel Erosion
The release of growth factors from these hydrogels in vitro
has also been investigated. Although covalently crosslinked,
heparin-containing hydrogels have been shown to be useful
for release of bFGF, physically crosslinked hydrogels could
provide an alternative protein-delivery matrix without the
need for potentially toxic crosslinking reagents.
The bFGF release and hydrogel erosion experiments were
performed at 4° C. in 24-well polystyrene assay plates. A 2.5
wt % solution of PEG-LMWH with bFGF was prepared via
dissolving PEG-LMWH and bFGF in PBS at a final molar
ratio of approximately 1:1,500,000 (bFGF to LMWH). Sec-
ondly, a 5 wt % solution of PEG-PF4ZIP (or other PEG-HBP)
in PBS was added to the PEG-LMWH/bFGF at a ligand molar
ratio of 8:1 (LMWH: PF4ZIP dimer). Other molar ratios can
also be used, depending upon the desired rate of release of the
growth factor and/or desired rate of erosion of the network.
Assuming that all HBPs on the PEG-HBP termini bind
LMWH, the molar ratio of bFGF to available LMWH in the
PEG-LMWH/PEG-HBP hydrogels is approximately
1:1,300,000.
Data from studies of bFGF release from PEG-LMWH/
PEG-HIP and PEG-LMWH/PEG-PF 4ZIP hydrogels are
summarized in FIG. 23. As shown in the figure, a burst release
of bFGF ranging from 10 to 25% (depending on gel identity)
is observed, followed by a slow release of bFGF over 10 days,
to a maximum measured release ranging from approximately
20 to 35%. Such release profiles are of potential use in
neovascularization, wound repair, and tissue engineering
applications. As shown in FIG. 23, the bFGF is released
slightly more quickly from the PEG-LMWH/PEG-PF4ZIP
hydrogels than from the PEG-LMWH/PEG-HIP hydrogels,
indicating that the rates of release of growth factor from these
hydrogels are tunable based on hydrogel composition. The
PEG-LMWH/PEG-HIP hydrogel demonstrates higher stor-
age and loss moduli than the PEG-LMWH/PEG-PF4ZIP
hydrogels. The observed burst release is similar in value to
previously reported burst release in other heparinized hydro-
gel system, and the linear release following the initial burst in
those hydrogel systems has been successfully applied to
stimulate cell proliferation.
Hydrogel erosion kinetics are also shown in FIG. 23. In the
case of the PEG-LMWH/PEG-PF4ZIP hydrogels, PEG-
LMWH-Alexa Fluor 350 was pre-mixed with PEG-LMWH
at a weight ratio of 1:158 to facilitate tracking of the eroded
PEG-LMWH via fluorimetry. The erosion profile of the PEG-
LMWH/PEG-HIP hydrogels was determined gravimetrically
in the transwell assay format in conjunction with the bFGF
release experiments. As shown in the figure, a burst erosion of
10 to 30% is initially observed (depending on hydrogel com-
position), followed by a slow erosion to a maximum of 30 to
50% (again, depending on hydrogel composition). As is also
5 indicated in this figure, the growth factor release is directly
correlated to the erosion of the hydrogel, and can therefore be
controlled by modulating hydrogel mechanical properties.
Modulating the affinity of the growth factor to the hydrogel
will also serve as an additional strategy to control release
10 rates.
Growth factors released from hydrogels of these general
compositions have also been shown to be bioactive, indicat-
ing the utility of these matrices in desired applications. For
example, bFGF released from PEG-LMWH functionalized
15 hydrogels (covalently crosslinked model systems) (proce-
dure for covalent crosslinking is provided in N. Yamaguchi,
K. L. Kiick, Polysaccharide poly (ethylene glycol) star
copolymers as scalblds for the production of bioactive hydro-
gels, Biomacromolecules 6 (4) (2005) 1921-1930, which is
20 incorporated herein by reference) has been shown, via MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) proliferation assays, to increase proliferation of
HUVECs (human umbilical vein endothelial cells) in a
bFGF-dose-responsive manner. In these assays, the amount
25 of yellow MTT oxidized to purple formazan is measured
spectrophotometrically as a function of the amount of bFGF
loaded in the hydrogel. Average increases in formazan salt
formation ranged from 1.5 to 4 fold in the bFGF proliferation
experiments. In another set of experiments, VEGF released
30 from the PEG-LMWH/VEGF hydrogels has been shown to
increase the rate of proliferation of porcine aortic endothelial
(PAE) cells in DMEM media. Assays were conducted in a
transwell assay format as described in N. Yamaguchi, K. L.
Kiick, Polysaccharide poly (ethylene glycol) star copolymers
35 as scalblds for the production of bioactive hydrogels, Biom-
acromolecules 6 (4) (2005) 1921-1930. Measured increases
in the proliferation rate, assessed via cytometry, have ranged
from 25-50%. These results complement and are similar to
the results obtained in Example 3, which indicate the bioac-
40 tivity of growth factor-loaded electrospun matrices. Similar
bioactivity of any growth factor sequestered in these matrices
is expected, based on these results, and on the general obser-
vation of growth factor activity preservation in heparinized
matrices.
45	 What is claimed is:
1. A crosslinked matrix comprising at least two compati-
bilizing polymer-LMWH conjugates, wherein the compati-
bilizing polymer comprises PEG, and at least one crosslink-
ing compound wherein each compatibilizing polymer-
5o LMWH conjugate is capable of assembly and comprises at
least one compatibilizing polymer covalently bonded to at
least one LMWH molecule, wherein each of the compatibi-
lizing polymer-LMWH conjugates are partially nonco-
valently crosslinked with the same crosslinking compound,
55 and wherein the crosslinking compound is an incorporated
molecule comprising a heparin-binding growth factor or a
heparin-binding compatibilizing polymer-peptide conjugate.
2. The crosslinked matrix of claim 1 wherein the crosslink-
ing compound comprises a heparin-binding compatibilizing
60 polymer-peptide conjugate.
3. The crosslinked matrix of claim 2 wherein the heparin-
binding compatibilizing polymer-peptide conjugate com-
prises PF4zjP, HIP, orATIII.
4. The crosslinked matrix of claim 1 wherein the LMWH
65 has an average molecular weight of about 10,000 daltons.
5. The crosslinked matrix of claim 1 wherein the compati-
bilizing polymer comprises four-arm star PEG.
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6. The crosslinked matrix of claim 1 wherein the LMWH
has an average molecular weight of about 3,000 daltons.
7. The crosslinked matrix of claim 1 wherein the incorpo-
rated molecule release is directly correlated to the erosion of
the matrix.	 5
8. The crosslinked matrix of claim 1 wherein the incorpo-
rated molecule release is directly correlated to cell-receptor
interactions with the matrix.
9. The crosslinked matrix of claim 2 wherein the heparin- 
10binding compatibilizing polymer-peptide conjugate is
capable of assembly and comprises at least one compatibiliz-
ing polymer covalently bonded to at least two heparin-bind-
ing peptides.
10.A crosslinked matrix comprising at least three compati- 15
bilizing polymer-LMWH conjugates, wherein the compati-
bilizing polymer comprises PEG, at least one incorporated
molecule comprising a heparin-binding growth factor and at
least one heparin-binding compatibilizing polymer-peptide
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conjugate wherein each compatibilizing polymer-LMWH
conjugate is capable of assembly and comprises at least one
compatibilizing polymer covalently bonded to at least one
LMWH molecule, wherein at least two of the compatibilizing
polymer-LMWH conjugates are partially noncovalently
crosslinked with the same incorporated molecule, wherein at
least two of the compatibilizing polymer-LMWH conjugates
are partially noncovalently crosslinked with the same hep-
arin-binding compatibilizing polymer-peptide conjugate.
11. The crosslinked matrix of claim 1 wherein the
crosslinking compound comprises a heparin-binding growth
factor.
12. The crosslinked matrix of claims 10 or 11 wherein the
growth factor comprises fibroblast growth factor, vascular
endothelial growth factor, heparin-binding epidermal growth
factor, transforming growth factor, acidic fibroblast growth
factor or basic fibroblast growth factor.
